

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/53, 33/537, 33/541, 33/543, 33/493, C07K 16/26	A1	(11) International Publication Number: WO 99/39202 (43) International Publication Date: 5 August 1999 (05.08.99)
--	----	--

<p>(21) International Application Number: PCT/US99/02279</p> <p>(22) International Filing Date: 3 February 1999 (03.02.99)</p> <p>(30) Priority Data: 09/018,122 3 February 1998 (03.02.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/018,122 (CIP) Filed on 3 February 1998 (03.02.98)</p> <p>(71) Applicant (for all designated States except US): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BIRKEN, Steven [US/US]; 120 Oneida Avenue, Dumont, NJ 07628 (US). MAYDELMAN, Yacov [RU/US]; Apartment #3B, 3040 Edwin Avenue, Fort Lee, NJ 07024 (US). KOVALEVSKAYA, Galina, I. [RU/US]; Apartment #5G, 850 West 176th Street, New York, NY 10033 (US).</p>	<p>O'CONNOR, John, F. [US/US]; 35 Clinton Place, New Rochelle, NY 10801 (US).</p> <p>(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).</p> <p>(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>
--	--

(54) Title: DETERMINATION OF THE AMOUNT OF hLH β CORE FRAGMENT IN A SAMPLE FROM A SUBJECT AND USES THEREOF

(57) Abstract

The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf in the sample; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DETERMINATION OF THE AMOUNT OF hLHB CORE FRAGMENT IN A
SAMPLE FROM A SUBJECT AND USES THEREOF

5

This application is a continuation-in-part application of U.S. Serial No. 09/018,122, filed February 3, 1998 the contents of which is hereby incorporated by reference.

10 The invention disclosed herein was made with Government support under NIH Grant Nos. HD15454, ES07589 and M01-RR00645, AG13783, ES07589, AG 12745, AG12222 HD15454. Accordingly, the U.S. Government has certain rights in this invention.

15

Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the the claims.

20 The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

25

Background of the Invention

With the extension of the human life span, women spend one-third of their lives beyond the reproductive years. The transition into menopause, a normal process of aging, is associated with physical risks and psychological adjustments. It is critical to improve understanding of the these changes. However, there is a lack of diagnostic tools for monitoring the temporal stages in the history of menopause despite the importance of this transition period. There is no reliable test to determine how close a woman is to menopause. Clinical decisions for treatment of perimenopausal women today are based chiefly upon subjective symptoms rather than objective diagnostic tests.

40

-2-

There is a lack of adequate chemical markers for defining the menopausal state since neither serum gonadotropins, estradiol, nor inhibin A or B levels are adequate for diagnosis unless daily sampling is performed for prolonged periods of time (Burger, 1996;. Burger, et al., 1995; Burger, 1994a; Burger, 1994b; Hee, et al. 1993; Metcalf, 1988). A number of studies of women during the periovulatory period have indicated that the currently used biochemical markers of menopause are inadequate (Burger, 1996;. Burger, et al., 1995; Burger, 1994a; Burger, 1994b; Hee, et al. 1993; Metcalf, 1988; Santoro, et al. 1996). Gonadotropin levels fluctuate from postmenopausal concentrations back down to levels found in normal, young cycling women (Burger, 1996; Burger, et al., 1995; Burger, 1994a; Metcalf, 1988; Metcalf, et al. 1982; Metcalf and Donald, 1979). What appear to be normal ovulatory cycles may follow prolonged anovulatory periods coincident with postmenopausal concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) (Burger, 1996;. Burger, et al., 1995; Burger, 1994a; Burger, 1994b; Metcalf, 1988; Metcalf, and Donald, 1979; Metcalf, et al. 1981a). Some investigators declare that all current biochemical measurements have little predictive value during the menopausal transition because of the great variations in levels of steroids and gonadotropins. (Burger, 1996;. Burger, 1994a; Burger, 1994b; Hee, et al. 1993;. Metcalf, and Donald, 1979; Metcalf, et al. 1981b; Metcalf, 1979).

Although elevations in certain serum gonadotropin levels reflecting gametogenic failure usually occur several years before a decline in estrogen and irregular cycling begins, measurement of serum gonadotropin levels, estrogen, and inhibins A and B have limited value to the practicing physician. A reliable test is essential to differentiate a premenopausal woman from a woman very early in perimenopause or the latter from one in the middle of the transition; menopausal changes could be placed in relation to the stage of menopausal transition. This would help to resolve, for

example, whether treatment for osteoporosis should begin much earlier or that hormone replacement therapy should begin at a different time rather than based on symptomatic discomfit. The present invention solves these problems by providing urinary-based immunoassay methods and assay kits.

Human gonadotropins undergo metabolic transformations, which result in the presence of several smaller, structurally and immunologically related forms in the urine. A major form of urinary hCG-associated immunoreactivity is an epitope on a molecule smaller than heterodimeric hCG (Birken et al., 1996; O'Connor et al., 1994; Schroeder and Halter, 1983). This molecule has been identified as an hCG beta core fragment (hCG β cf) (Birken et al., 1988; Blithe et al., 1988). In normal pregnancy, the core fragment constitutes a major mole fraction of urinary hCG excretion (Kato and Braunstein, 1988). Using polyclonal antisera raised against hCG β cf, immunoreactive beta core like activity can be detected in both postmenopausal women and in the periovulatory period of the normal menstrual cycle (Iles et al., 1992; Neven et al., 1993). However, some immunoreactivity results from cross-reactivity with the polyclonal hCG β cf antibodies. An hLH beta core fragment (hLH β cf) has been isolated from human pituitaries and a panel of monoclonal antibodies has been generated (Birken et al., 1993a; Kovalevskaya et al., 1995).

The corresponding urinary fragment is inferred from mass spectral and immunochemical analysis of chromatographically separated urinary forms. Physico-chemical characteristics, primarily mass spectral and chromatographic, indicate that the pituitary and urinary forms of hLH β cf have a different structure, probably in the carbohydrate moieties. The carbohydrate moiety of the pituitary hLH β cf resembles that of pituitary hLH β rather than displaying the degraded carbohydrate chains present in urinary hCG β cf. The endogenous urinary core material is extremely stable to repeated freeze/thaw cycles and prolonged storage at 4°C or

-4-

at room temperature. HLH β cf cross-reaction with some hLH or hLH β monoclonal antibodies may well interfere with the accurate estimation of the day of hLH surge when urinary tests are utilized. The expression of hLH β cf in the urine of both reproductive and postreproductive age women and in men, is now characterized employing assays highly specific for the pituitary form of the fragment.

Analysis of the metabolites of the gonadotropins excreted into urine can help to distinguish between healthy and abnormal physiological states. For example, the hCG β core fragment (hCG β cf) is present at high levels in the urine of normal pregnant women (Kato et al., 1988) but, also, occurs abnormally in the urine of nonpregnant patients with a variety of malignancies (O'Connor et al., 1988, Cole et al., 1988a, 1988b, 1990). Until now, it has not been possible to distinctly measure one of the fragments in the presence of the others. For example, the utility of the hCG β cf molecule as a marker of malignancies in postmenopausal women has been compromised by the cross-reactions of antibodies elicited to the hCG β cf with a molecule of similar structure and size (presumably the homologous fragment of hLH) excreted by normal postmenopausal women in their urine. Consequently, the high threshold measurement compromised the ability of hCG β cf to serve as a cancer marker in this important patient population. Distinguishing hLH β cf from an hCG β cf, therefore, is of great value. A preponderance of hLH β cf may indicate a normal state while a major mole fraction of the hCG fragment may be associated with malignancy (Birken et al., 1993b). The present invention provides a method to make such a distinction. Immunological analysis of the hLH β cf in normal cycling women, as compared with infertile patients, may identify a metabolic marker associated with an abnormal state (i.e. an ovulatory cycles, polycystic ovarian disease). Antibodies to the hLH β cf, isolated from pituitary extract, can also be used to measure such a molecule in urine.

-5-

Methods for specific immunometric assays which report the levels of expression of this new hLH molecular form, hLH β cf, in men and women at different stages of their reproductive history are described herein. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and in men and to distinguish between normal and abnormal physiological states.

10 In addition, these methods to visualize LH fragment in plasma differentiates LH fragment derived directly from pituitary from that derived by peripheral cleavage of LH. hLH β cf may circulate in plasma.

15 The methods described herein measure the stable metabolic products of LH which are excreted into urine usually at much higher concentrations than the parent hormones, themselves, are found in urine or blood. These assays do not use heterodimeric hormones which are unstable, unless
20 supplemented by stabilizers such as glycerol, because they dissociate into their constituent, non-covalently bound subunits, especially under acid conditions or upon freeze thaw cycles. Urinary metabolic forms represent end-products of a degradative process. The forms explored have proven to
25 be stable unlike the parent hormones which can dissociate into free subunits greatly complicating urinary measurements. Antibodies specific for hLH beta core fragment some of which are referred to in the present application, have been detailed in the related co-pending
30 U.S. application No. 08/763,669 filed December 11, 1996, the content of which is hereby incorporated by reference. In particular, related co-pending U.S. application No. 08/763,669 filed December 11, 1996, describes monoclonal antibodies designated B505, B503 and B504 which are produced
35 by the hybridoma cell lines accorded ATCC Accession No. 12000, 11999 and 12002 respectively and details methods for their production and use, which is hereby incorporated by reference.

This invention also provides monoclonal antibodies, B503, 504 and 505. This invention also provides hybridoma cell lines producing the monoclonal antibody B503, 504 and 505. These hybridoma cell lines were deposited on December 11, 1995 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.S. under the provision of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. These hybridoma have been accorded with ATCC Accession Nos. 11999, 12002 and 12000 respectively.

The present invention takes advantage of the natural metabolic processing of LH as a means of improving the diagnosis of women in perimenopause as well as to assess patterns of metabolites useful for monitoring estrogen replacement therapy.

The core fragment of hLH β is useful as a urinary marker for many different physiological states including disease, as markers of the state of senescence the ovary.

As used in this application hLH β core fragment (hLH β cf) means and includes a fragment of human luteinizing hormone (hLH) which is produced as a metabolite and which has been isolated from human pituitaries (Birken et al. 1993; Kovalevskaya et al., 1995) as well as related molecules and other metabolites of hLH which may be used as markers of menopause.

30 Summary of the Invention

This invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the

-7-

amount of complex formed, so as to thereby determine the amount of hLH β cf in the sample; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

This invention further provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject comprising the steps of: (a) contacting a urine sample from the subject with a capturing antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf under conditions permitting binding of the antibody with any hLH β cf present in the sample wherein the capturing antibody is bound to a matrix (b) separating hLH β cf bound to the matrix bound capturing antibody from hLH β cf not so bound; (c) contacting the hLH β cf bound matrix to the capturing antibody with a second antibody which specifically binds to hLH β cf that is bound to the capturing antibody without cross reacting with hLH, hLH β or hCG β cf under conditions permitting binding of the second antibody to hLH β cf bound to the capturing antibody; (d) measuring the amount of the second antibody bound to the hLH β cf that is bound to the matrix bound capturing antibody so as to thereby determine the amount of hLH β cf in the sample; and (e) comparing the amount of hLH β cf in the subject's sample determined in step (d) with either (i) the amount determined for a sample from a known postmenopausal female subject or (ii) the amount determined

for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and the amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

This invention also provides a method for determining the likely timing of the onset of menopause for a perimenopausal female subject comprising: (a) obtaining a series of samples from the female subject over a period of time; and (b) determining the amount of hLH β cf in each of the samples, the presence of elevated levels of basal hLH β cf in each of the samples indicating that the onset of menopause in the subject is likely to occur in the near future. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

This invention further provides a method for assessing ovarian function in a subject comprising the steps of: (a) contacting a sample from a subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of molecule in the sample; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for a sample from a subject with normal ovarian function or (ii) the amount determined for a sample from a subject with abnormal ovarian function, wherein an amount of hLH β cf in the sample similar to amount of hLH β cf in the sample from subjects having normal ovarian function indicates normal

-9-

ovarian function, and amounts of hLH β cf in the sample similar to amounts of hLH β cf having abnormal ovarian function indicates abnormal ovarian function for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

This invention also provides a method for determining the efficacy of hormone replacement therapy in a perimenopausal female subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf; and (c) comparing the amount of hLH β cf measured in step (b) with either (i) the amount determined for a sample from a subject taken prior to the commencement of therapy or (ii) the amount determined for a sample after a prior course of therapy (iii) the amount determined for a sample from a known premenopausal female subject or (iv) the amount determined for a sample from a known postmenopausal female, wherein differences in the amounts of hLH β cf in the sample indicate efficacy of the hormone replacement therapy for the subject; amounts of hLH β cf in the sample similar to amounts of hLH β cf samples from known premenopausal subjects indicates efficacy of the hormone replacement therapy for the subject; amounts of hLH β cf molecule in the sample similar to amounts of hLH β cf in the sample from known postmenopausal subjects indicates lack of efficacy of the hormone replacement therapy for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

Finally, this invention provides a diagnostic kit for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount

-10-

of hLH β cf in a sample from the subject comprising: (a) a solid matrix to which an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf is bound; and (b) a second antibody labeled with a detectable marker; and (c) reagents permitting the formation of a complex between the antibody and hLH β cf. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

Brief Description of the Figures

Figure 1.

The hLH β core fragment isolated from human pituitary extracts. Antibodies were developed to this pituitary hLH β core fragment which recognize an homologous fragment of 10K MW in postmenopausal and perimenopausal as well as periovulatory urine. (Seq.ID.No.:1). Cleaved bonds are indicated by the arrows. Peptide portions deleted from the structure are in bold and crossed out. The remaining peptides are represented as Seq.ID.No.:2.: [Arg Pro Trp Cys His Pro Ile Asn Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr] [Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Gly Pro Cys]

Figure 2.

Reverse phase of periovulatory and postmenopausal urine fractions which contain hLH β cf activity and pituitary hLH β cf. All fractions assayed in B505-B503 assay. The open circles denote the elution position of hLH β cf derived from the pituitary. The closed circles and squares denote the elution positions of hLH β cf partially purified from urine.

-11-

The difference in elution positions denotes a structural difference (probably carbohydrate differences) between the urinary and pituitary forms. The pituitary form elutes later while the urinary form in postmenopausal and premenopausal women elutes in identical positions. The pituitary form contains carbohydrate and sulfate similar to hLH β . However, the urinary form may have trimmed carbohydrate.

Figures 3A-3K.

Measurements of the concentration of hLH β cf in the first morning void urine of seven premenopausal (Figures 3A-3G), two perimenopausal women (Figures 3H-3I) and two postmenopausal women (Figures 3J-3K). The premenopausal women were measured from the first day of menses.

Figure 4.

Typical hLH β cf pattern observed in the first morning void urines of a postmenopausal woman analyzed for 60 days. The assay was repeated weeks later after freeze-thaws. Concentrations and patterns observed were the same as for freshly collected urine specimens. Similar collections from four patients with premature ovarian failure exhibited very similar profiles for this metabolite, except with generally higher concentrations.

Figures 5A-5E.

Hormone profiles in the urine of normally cycling women (n=15). Concentrations were presented as mean \pm standard error (SE), fmol/mg creatinine (fmol/mg C). hLH concentration was measured using two different IRMAs (n=8 for hLH-2 assay). Steroid hormone ratio was calculated using estrone-3-glucuronide (E₁-3-g) and pregnandiol-3glucuronide (Pd-3-G) $\times 10^3$ X. Day 0 is the day of hLH surge.

Figure 6.

Box plot of urinary hLH β cf values in the first ten days of cycle for ten normally cycling women. Day 1 is the first day of menses. The Box extends to the 25th and 75th percentile. The upper and lower bars indicate the 90th and 10th percentile respectively. The upper and lower symbols indicate 95 and 5 percentile points respectively. The solid line inside the box marks the value of the 50th percentile. The dashed line represents the mean of concentration.

Figures 7A-7D.

The urinary hLH molecular forms profile in two subjects (patient #75-3, patient #67-5) who did not express measurable intact hLH in either of the hLH assays (Figs. 7A and 7C respectively). Both hLH free β subunit and hLH β cf surges are clearly apparent. Figures 7B and 7D illustrate the corresponding urinary steroid metabolite patterns for the cycles. It can be inferred from the steroid profiles that the subjects experienced normal ovulatory cycles, even in the absence of detectable intact hLH. Concentrations were normalized to creatinine. Day 1 is the first day of menses.

Figure 8.

Box plot of urinary hormone values for postmenopausal women. The box extends to the 25th and 75th percentile. The upper and lower bars indicate the 90th and 10th percentile respectively. The upper and lower symbols indicate 95 and 5 percentile points respectively. The solid line inside the box marks the value of the 50th percentile. The dashed line represents the mean of concentration (n=107). The wide range of Y values necessitated use of a log scale.

Figures 9A-9B.

Urinary hormone profile of a patient obtained using

-13-

monoclonal antibody based IRMAs (Figure 9A) and RIA using on the base of polyclonal antibodies (provided by NIDDKD) to hLH and hLH β (Figure 9B). Concentrations were normalized to creatinine. Day 0 is the day of the hLH surge.

Figure 10.

Binding of hLH and hLH β specific antisera (NIDDKD) with hLH β cf in RIA format.

Figures 11A-11B.

hLH and hLH β cf in serum and urine of the same patient. The blood levels of intact hLH (open circles) and hLH β cf (closed circles) are illustrated in Figure 11A. Not that there is an insignificant amount of the hLH β cf was detected in the blood. Figure 11B illustrates the urinary values for hLH and hLH β cf in the urine for the same days of collection. The surge of hLH (day 0) and the surge of hLH β cf (1-2 days later) were detected in urine, but the peak of hLH β cf lags behind that of the intact hLH by 2-3 days, suggesting that the origin of urinary hLH β cf is a consequence of the peripheral or renal metabolic processing of intact hLH.

Figures 12A-12C.

Profile of woman JD classified as perimenopausal and analyzed by the hLH β cf urinary assay. Consecutive first morning void urines were collected. The first day of collection was at random and not correlated to first day of menses as the ten day collections. Both patient JD and patient MJU (see Figure 13) were over 45 yrs old but were having regular menstrual cycles. Both women have two LH surges and two ovulations as shown by the middle pattern of steroids. The women were followed over time. Patient JD who displayed a clear postmenopausal-like pattern of hLH β cf concentration in urine, began to experience irregular cycles within six months of this collection and became postmenopausal

-14-

within two years.

Figures 13A-13C.

5 Patient MJU was classified as perimenopausal. Figure
13A shows the hLH β cf pattern observed in first morning
void urines collected in 1991. This pattern is similar
to that observed for premenopausal women. MJU is still
not postmenopausal at the present time but is
10 experiencing irregular cycles. Conventional urinary
measurements of hLH by the Delfia assay did not show
differences between patient JD (see Figure 12) and
patient MJU while the hLH β cf assay of the present
invention correctly predicted that JD was closer
15 (exhibited temporal proximity) to menopause despite
having regular cycles at the time of urine collection.
Additional patients exhibited similar profiles.

Figures 14A-14F.

20 Measurements of the concentration of hLH β cf in the
first morning void urine of three women before Estrogen
replacement therapy (ERT) (Figures 14A,14C,14E) and
after ERT (Figures 14B,14D,14F). The area under the
curve was calculated and is indicated. The profile for
patient LK displays an area under the curve of 3050
25 before ERT and 1650 after ERT (Figures 14A-14B). The
profile for patient VP displays an area under the curve
of 1350 before ERT and 280 after ERT (Figures 14C-14D).
The profile for patient NP displays an area under the
curve of 3200 before ERT and 3260 after ERT (Figures
30 14E-14F).

Figure 15.

35 Immunochemical characterization of first morning void
daily samples for a 60 day interval of a woman
considered perimenopausal in 1991. The upper panel A
is a graph of the hLH β cf urinary concentration each day
(normalized to creatinine) while the middle panel B is

-15-

that of steroid conjugates E1 and PDG. The lowest panel C shows the urinary hLH concentration as measured by DELFIA assay. This pattern resembles that of premenopausal women.

5
Figure 16.

Panel A. Pattern of hLH β cf concentration in first morning void samples of a postmenopausal woman. The assay was conducted twice (1st and 2nd runs as indicated on Y-axes) with a time separation of 6 weeks. This study indicates the stability of the urinary hLH β cf measurement over time and between assays. Panel B. Urinary hLH as measured by the DELFIA assay (see methods).

10
15
Figure 17.

Young woman with premature ovarian failure. Panel A. Typical postmenopausal concentrations of the hLH β cf are observed in this 60 day first morning void urine collection. Panel B represents hLH measurements made by the DELFIA assay (see methods). There is no pattern match between urinary hLH and urinary hLH β cf (considering the expected 1-2 day delay in hLH β cf excretion after a surge of circulating hLH).

20
25
Figure 18.

Immunochemical characterization of first morning void samples of a perimenopausal woman with data presented as described in the legend to figure 1. Panel A show hLH β cf measurements that are similar to those in postmenopausal women. Panel B show patterns of urinary steroid conjugates of estriol and progesterone. Panel C illustrates measurement of urinary hLH by the DELFIA assay (see methods).

-16-

Figure 19.

Patterns of excretion of the hLH β cf in first morning void collections of three women. Panel A, premenopausal; Panel B, perimenopausal; Panel C, postmenopausal. Premenopausal is always easily distinguished from postmenopausal based on the concentrations of hLH β cf and the area under the peaks. The perimenopausal women fall in between. In this case, the perimenopausal woman resembles the postmenopausal pattern and is presumed to be close to menopause.

Figure 20.

Graphs are presented for 5 postmenopausal women who were asked to collect samples of each urination during a 2 day time period. The concentration of the hLH beta core fragment appears on the Y-axis while the time of collection, as a 24 hour clock, appears on the X-axis. It appears that collection of urine specimens during the day is quite similar in pattern to the 10 day first morning void urine collection protocol. It may be possible to conduct the sampling design in a more convenient fashion by sampling consecutive urine specimens for a 1-2 day period of time rather than over 5-10 days.

Detailed Description of the Invention

This invention provides a method for predicting the likely timing of the onset of menopause for a premenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf in the sample; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

In an embodiment of this invention step (a) comprises contacting the sample with an antibody which specifically binds a region of hLH β cf comprising a protein and carbohydrate moiety.

In a further embodiment the antibody is monoclonal antibody B505 produced by hybridoma B505 (ATCC No. 12000).

In a further embodiment, step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is

-18-

measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.

5 In a further embodiment the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, an aggregate sample of the first morning void urine samples for five or more consecutive days, or a
10 collection of all urinations consecutively with time noted for 24-48 hours.

In a further embodiment, the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

15 In a further embodiment the detectable marker is the radioactive isotope I^{125} .

This invention further provides a method for predicting the
20 likely timing of the onset of menopause for a premenopausal female subject comprising the steps of: (a) contacting a urine sample from the subject with a capturing antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf under conditions
25 permitting binding of the antibody with any hLH β cf present in the sample wherein the capturing antibody is bound to a matrix (b) separating hLH β cf bound to the matrix bound capturing antibody from hLH β cf not so bound; (c) contacting the hLH β cf bound matrix to the capturing antibody with a
30 second antibody which specifically binds to hLH β cf that is bound to the capturing antibody without cross reacting with hLH, hLH β or hCG β cf under conditions permitting binding of the second antibody to hLH β cf bound to the capturing antibody; (d) measuring the amount of the second antibody
35 bound to the hLH β cf that is bound to the matrix bound capturing antibody so as to thereby determine the amount of hLH β cf in the sample; and (e) comparing the amount of hLH β cf in the subject's sample determined in step (d) with either

-19-

(i) the amount determined for a sample from a known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and the amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

In one embodiment the capturing antibody specifically binds a region of hLH β cf comprising a protein portion and a carbohydrate moiety

In a further embodiment, the capturing antibody is monoclonal antibody B505 produced by hybridoma B505 (ATCC No. 12000).

In a further embodiment separating hLH β cf bound to the matrix bound capturing antibody from unbound hLH β cf comprises the steps of (a) removing of the sample from contact with the matrix; and (b) washing the matrix with an appropriate buffer to remove unbound hLH β cf.

In a further embodiment the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.

In yet a further embodiment the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridoma B503 (ATCC No.11999) and B504 (ATCC

No. 12002) respectively.

In a further embodiment a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

5

In a further embodiment radioactive isotope is I^{125} .

10

This invention further provides a method for determining the likely timing of the onset of menopause for a perimenopausal female subject comprising: (a) obtaining a series of samples from the female subject over a period of time; and (b) determining the amount of hLH β cf in each of the samples, the presence of elevated levels of basal hLH β cf in each of the samples indicating that the onset of menopause in the subject is likely to occur in the near future. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

15

20

In a further embodiment step (b) comprises: (a) contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β , or hCG β cf, under conditions permitting formation of complex between the antibody and hLH β cf; and (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf in the samples; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, the stable presence of elevated levels of basal hLH β cf indicating temporal distance from the onset of menopause in the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

25

30

35

In a further embodiment in step (a) the antibody is bound to

-21-

a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.

In a further embodiment the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.

in a further embodiment the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridoma B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.

In a further embodiment the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

In a further embodiment the detectable marker is the radioactive isotope is I^{125} .

This invention further provides a method for assessing ovarian function in a subject comprising the steps of: (a) contacting a sample from a subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of molecule in the sample; and (c) comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for a sample from a subject with normal ovarian function or (ii) the amount determined for a sample from a subject with abnormal ovarian function, wherein an amount of hLH β cf in

-22-

the sample similar to amount of hLH β cf in the sample from subjects having normal ovarian function indicates normal ovarian function, and amounts of hLH β cf in the sample similar to amounts of hLH β cf having abnormal ovarian function indicates abnormal ovarian function for the subject. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

10 In a further embodiment in step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.

20 In a further embodiment the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days or an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.

25 In a further embodiment the abnormal ovarian function is hyperactivity or hypoactivity.

30 In a further embodiment the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridoma B503 (ATCC No. 11999) or B504 (ATCC No. 12002) respectively.

35 In a further embodiment the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

In a further embodiment the detectable marker is the radioactive isotope is I^{125} .

25

30

In a further embodiment the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two

-24-

consecutive days, or an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.

5

In a further embodiment the replacement hormone therapy comprises therapy with estrogen and second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridoma B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.

10

In a further embodiment detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.

15 In a further embodiment the detectable marker is the radioactive isotope is I^{125} .

Finally, this invention provides a diagnostic kit for predicting the likely timing of the onset of menopause for a premenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising: (a) a solid matrix to which an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf is bound; and (a) a second antibody labeled with a detectable marker; and (a) reagents permitting the formation of a complex between the antibody and hLH β cf. As described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

20

25

30

In a further embodiment the diagnostic kit of further comprises control sample(s) selected from the group consisting of premenopausal sample(s), perimenopausal sample(s), postmenopausal sample(s) and male sample(s).

35

In a further embodiment the second antibody in the diagnostic kit labeled with a detectable marker is the

-25-

monoclonal antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.

In a further embodiment the detectable marker in the diagnostic kit is a radioactive isotope, enzyme, magnetic bead, dye or biotin.

In a further embodiment detectable marker in the diagnostic kit is the radioactive isotope is I^{125} .

A monoclonal antibody, B-505, is produced by the hybridoma cell designated ATCC accession No. HB-12000. This hybridoma cell line was deposited on December 11, 1995 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S., under the provision of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purpose of Patent Procedure.

hLH beta core fragment (hLH β cf), isolated from human pituitaries is homologous to the hCG beta core fragment (hCG β cf). Antibodies to the hLH β cf, have been developed which are applied in sensitive assays including immunoradiometric assays for urinary measurements. One of the antibodies recognizes an epitope on the hLH β cf, which is not present on the hCG β cf, hLH, or hLH β . This specific hLH β cf antibody acts cooperatively with other newly-developed antibodies to produce an assay with a sensitivity of 1 fmol/ml of hLH β cf. This specificity makes it possible to measure hLH β cf in urine in the presence of hLH, hLH beta, or the hCG β cf. Although the hLH β cf used to develop specific antibodies was purified from pituitaries, the assays developed recognize this metabolite in urine. Measurements of heterodimeric hLH as compared to hLH β cf in the urine of cycling women indicated that the concentration of hLH β cf rose as high as 6-7 times the concentration of hLH starting a day after the midcycle surge. The novel measuring systems described herein allow the precise quantitation of this hLH

-26-

metabolite in urine.

Three groups of women were analyzed: young cycling premenopausal, perimenopausal (as defined by current clinical and age-related criteria), and postmenopausal women. The appearance of the hLH β cf in the urine of all three groups of women was pulsatile on a daily basis when measured in first morning void urine specimens. This was unexpected since hLH was pulsatile on an hourly basis in blood. Both the pattern of pulsatility and the amplitude of the pulses differed between young cycling women and postmenopausal women. Statistical analyses indicated that the wide range of differences between postmenopausal and premenopausal women made it possible to discriminate among the three groups of women. Postmenopausal women can be sampled for any ten day interval while cycling women can be sampled during the follicular phase. Data indicates drastically different qualitative and quantitative patterns of premenopausal and perimenopausal patients closest to menopause. Perimenopausal women displayed postmenopausal patterns in many cases. Women with premature ovarian failure exhibited a pattern similar to that seen for postmenopausal women, but with a distinguishing higher levels of hLH metabolite. Treatment of women with GnRH agonist peptide appeared to expel the hLH β core fragment directly from the pituitary. This demonstrates potentially two origins of this molecular form of hLH, both directly from the pituitary and from breakdown of circulating hLH in the kidney or other peripheral tissue compartments. A chromatographic technique was developed to separate the hLH β core fragment generated in the pituitary from that which usually appears in the urine of postmenopausal women.

This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow

thereafter.

EXPERIMENTAL DETAILSExample 1. Predicting Onset of Menopause Using a Urinary hLH B Core Fragment Assay

5 Measuring hLH β Core Fragment In Urine. Although immunological evidence indicated the presence of a β subunit fragment of hLH in the urine of postmenopausal women, no direct evidence that the molecules came from hLH and not from hCG was available until now (Iles, et al., 1992; 10 Kovalevskaya, et al., 1995; Neven, et al., 1993). The presence of this approximately 10,000 M.W. molecule was apparent on gel filtration chromatography and presented a background threshold problem in the application of assays for the hCG β core fragment as a potential cancer marker in 15 postmenopausal women (O'Connor, et al. 1994; Iles, et al., 1992; Birken, et al., 1993; Kovalevskaya, et al., 1995; Neven, et al., 1993). The specific measurement system for such a fragment from hLH differentiates it from the homologous fragment from hCG β which is known to be present 20 at high levels in the urine of pregnant women and in patients with hCG-secreting cancers including a variety of cancers of the reproductive system (O'Connor, et al. 1994; Stenman, et al., 1993 ;de Medeiros, and Norman, 1991; Birken, et al., 1993; Kovalevskaya, et al., 1995; Lee, et 25 al., 1991; Krichevsky, et al., 1991). Using pituitary tissue extracts as starting material, an hLH β core fragment whose structure appears in Figure 1 was successfully isolated. The specific measuring systems for the hLH β core fragment can be used in the presence of the hCG β core 30 fragment as well as in the presence of hLH (Kovalevskaya, et al., 1995). The hLH β core fragment assay can measure 1.3 fmol/ml of this epitope and cross-reacts only 1% with hLH β core fragment and less than 1% with hCG β core fragment. A MALDI-TOF delayed extraction reflector mass spectrometer has 35 been employed to visualize the sizes of the hCG and hLH β core fragments which are both broad peaks of 9500-10000 AMU. It has been possible to measure the size of the urinary form of the hLH β core fragment (also 10K in a partially

purified preparation).

The β fragment of hLH from human pituitaries (see, Figure 1, Seq.ID.No.:1) has been isolated and sensitive and specific two-site assays to this molecule have been developed (Birken, et al., 1993; Kovalevskaya, et al., 1995). The hLH β core fragment is homologous to the hCG fragment. The hLH β core fragment, isolated from a pituitary extract and its structure is slightly heterogeneous and is composed of residues 6-40 linked to 49-93 or 55-93 (Birken, et al., 1993). The hLH β core fragment is clearly detected in postmenopausal urine at high concentrations using antibodies to the similar metabolite of hCG (Iles, et al., 1992; Neven, et al., 1993). The hLH β cf epitope in urine is highly stable as is the hCG metabolite making it a very useful urinary marker. Subunit dissociation is not a problem with stable markers.

A very important characteristic of useful urinary assays is stability of the analyte. The hLH β cf exhibits a stable profile, making it far superior to the use of heterodimeric hormones. Parent hLH tends to dissociate, especially in urine. The stability of both the pituitary and the urinary forms of the hLH β cf is illustrated in Table I.

Table I

Storage Conditions for Stability Testing

Molecular Form	-80 C	29 days, 4 C	29 days, 22 C	1 day, 37 C	40 freeze/thaws
Pit. hLH β cf	153+/- 7.6	162+/- 7.8	163+/- 7.8	183+/- 2.4	155+/- 5.6
Urinary hLH β cf	243+/-34	199+/-11	203+/-13	290+/- 7.7	211+/-21

values expressed as means of concentrations of fmol/ml
+/- 1SD

-30-

In the urine of a normally cycling woman, hLH β cf appears starting with the LH surge and peaking generally 1-3 days after the urinary LH surge peak concentration. The urinary hLH β cf appears at concentrations 2-10 times that of hLH on a molar basis. Chromatographic separatory data based on different elution times on reverse phase high pressure liquid chromatography (HPLC) indicates that the urinary and pituitary forms of the hLH β cf differ. This difference may be within the carbohydrate moieties (see Figure 2). The hCG β core fragment is known to contain sugar moieties trimmed down to their mannose cores while the pituitary hLH β core fragment appears to contain sulfate and resemble the structure of hLH in carbohydrate. The size of the urinary form on mass spectrometry resembles that of the pituitary homolog (10K). The urinary form of hLH β cf may have trimmed carbohydrate.

Although antibodies were developed to the pituitary form of the hLH β core fragment, the antibodies react with great sensitivity to the 10,000 M.W. fragment which is present in the urine of postmenopausal women. This fragment elutes with a midpoint of fraction 65 on the gel filtration profile of a postmenopausal urine concentrate on Superdex 200. The hLH β cf from both a human pituitary extract and postmenopausal urine would both appear at high concentration in the identical area of fraction 65.

Studies of a series of normal ovulatory cycles indicated that the measurement of the hLH β cf in urine is much easier than the hLH surge in urine because of: (1) the high concentration of fragment, (2) its stability, and (3) some monoclonal antibodies do not recognize all forms of hLH and can miss the hLH surge. The instability of hLH is illustrated by the daily urine profile of a normal cycling woman whose urine contains on detectable heterodimeric hLH but only hLH β and hLH β cf. Studies of several ovulatory cycles shows that the hLH β core fragment is present at all times at a basal pattern level but at concentrations more

-31-

than an order of magnitude lower than the hLH β cf found in the urine of postmenopausal women (see Figures 3A-3K). This also illustrates paradigm of first morning void studies from day 1 of menses to day 10. While both premenopausal and postmenopausal women exhibit daily first morning urine hLH β cf concentrations in a pulsatile fashion, the concentrations are so dramatically different that summing areas under the peaks define non-overlapping area values allowing statistical differentiation of the two populations.

Daily first morning void urine specimens from perimenopausal and postmenopausal women for 60 consecutive days were measured urinary hLH with the Delfia Figure 10 system as well as steroids and creatinine and validated the serum Delfia kit for urine measurements using added glycerol as a stabilizer for heterodimeric hLH (Saketos, et al., 1994). Several complete cycles from premenopausal women and a number of ten day first morning voids from postmenopausal women and follicular phase ten day collections from premenopausal women were also collected. Statistical analyses of these patterns were conducted by determining the area under the peak for a ten day interval and then performing least squares analysis of variance with pair-wise post hoc comparisons. Statistically significant differences, after Bonferroni correction was found for premenopausal/postmenopausal comparisons. Power analyses for this study, which consisted of ten consecutive first morning void urines, menstrual days 1-10 for premenopausal and perimenopausal women, required log-transformed values. The test populations consisted of 13 premenopausal women, four perimenopausal and eight postmenopausal.

A 60 day random collection of first morning void urine from a postmenopausal woman was assayed (see Figure 4). The assay was repeated twice on the same samples weeks later after freeze thaws. The identical pulsatile pattern with the same concentrations was observed.

-32-

Expression of Urinary hLH β cf. A cohort of women was studied (n=15). A peak of hLH β cf was observed to occur over a 3-4 day period, commencing on the day of hLH surge and reaching a maximum value of 560 (SE 119) fmo/mg creatinine at 1-3 days post urinary intact hLH peak (see Figure 5). A peak of hLH free beta subunit (hLH β) was observed to occur simultaneously with that of the intact molecule. Although the levels of hLH β approximately those of the intact hormone, the levels of hLH β cf were several fold higher (see Figure 5).

A surge of hCG β cf immunoreactivity peaked two days post intact hLH, generally coincident with the peak of hLH β cf but at levels which were 100 fold less than those for hLH β cf. Since the cross-reaction of the hCG β cf immunoassay with the pituitary hLH β cf was determined to be 1-2%, and that the true cross-reactivity with the urinary form is unknown, it may be that the total signal detected in the hCG β cf assay is in fact due to cross-reaction with hLH β cf (Birken et al. 1996).

The urinary hLH surge was detected by A407-B207 (hLH-1) antibody configuration. Eight of the 15 cycles were rerun in a different antibody configuration assay B406-A201 (hLH-2). These assays were constructed using monoclonal antibodies to different hLH epitopes (See Table III). Both hLH-1 and hLH-2 assays gave the same day of hLH surge, but the concentration of hLH in two assays differed significantly (paired t-test, $P=0.0005$).

This observation further illustrates that the levels of hormone detected immunologically in urine reflect the differential conservation (or stability) of hLH epitopes excreted into urine and caution that monoclonal antibodies may be too specific to provide an accurate estimation of the level of all forms of hLH in either blood or urine

-33-

(Pettersson et al., 1991; Pettersson et al., 1992; Martin-Du-Pan et al., 1994; Costagliola et al., 1994; Mitchell et al., 1995; Barbe et al., 1995 Pettersson and Soderholm, 1991).

5 All cycles were characterized by irregular pulsations of hLH β cf. The basal level of hLH β cf in ten patients during first of the follicular phase (100 samples) was 32 (SE 4) fmo/mg creatinine, with a wide range of concentrations, reflecting the spikes of hLH occurring before the periovulatory surge of hLH β cf (Figure 6).

15 Examination of daily first morning urines from four women in which the hLH assays, indicated that ovulation occurred as judged by the inversion of the urinary estrogen/progesterone metabolite ratio (Baird et al., 1991). Data from two of the four women are presented in (Figure 7). Evidence from the urinary steroids that ovulation occurred suggested that one or more of the following occurred. The intact hormone may have been completely cleared by an alternative pathway. The intact hormone may have dissociated completely into subunits or been totally degraded into fragments prior to excretion. Alternatively, the antibodies used in these measurements, which were raised to the pituitary form of hLH, may have failed to recognize the urinary isoform of hLH present in the sample. That the lack of evidence for intact hLH was not a consequence of these subjects producing an isoform of hLH peak was found in other cycles tested from these subjects.

30 These cycles were characterized by the presence of a periovulatory peak of hLH β cf within the expected time interval. These results suggest that an assay incorporating the detection of all three urinary analytes would provide the most sensitive detection of periovulatory hLH. However, although hLH β is most often observed to peak coincident with

-34-

the intact molecule (Figure 5), it appears that it can occasionally occur one day earlier (Kovalevskaya et al., 1995). On the other hand, hLH β cf, usually peaked 1-3 days later than the intact molecule (Figure 5) and this midcycle peak of hLH β cf has been detected in all four cycles in which there was undetectable intact hLH in the urine (Figure 7).

The levels of intact hLH, hLH β , hLH β cf, and hCG β cf were evaluated in a total of 107 healthy postmenopausal women (Figure 8). The mean concentration of hLH β cf for the 107 postmenopausal women was 236 (SE 35) fmol/mg creatinine.

Urines collected from eleven normal males (age 20-60) yield a value of 41 (SE 13) fmol/mg creatinine (See Table II).

TABLE II
Concentration of hLH β cf in Urine

	Periovulatory urine, basal level	Periovulatory urine, surge	Postmenopausal urine	Male urine
Mean +/- SE, fmol/mg C	32 +/- 4	560 +/- 119	236 +/- 35	41 +/- 13
Size	100*	15	107	11

SE - standard error of mean; fmol/mg

C - concentration of hLH β cf normalized per mg creatinine;

* - days 1 to 10 from 10 women.

hLH and hLH β were measured in urine using IRMA's incorporating specific monoclonal antibodies (Figure 9A) and by RIA (Figure 9B), using polyclonal antisera directed against either intact hLH or hLH β , supplied by the National Hormone and Pituitary Program, NIDDKD. The RIA reagents were designed for serum assays and indicate a single day pre-ovulatory elevation of both hLH and occasionally hLH β in blood.

When these same reagents are employed for hLH or hLH β measurement in urine however, a broad peak for either

-35-

hormone was obtained. These observations can be explained by the presence of hLH β cf in the urine (Figure 9A). When Figures 9A and 9B are compared, it is apparent that the day of maximum hLH β by IRMA is different from the RIA value, probably due to the greater cross-reactivity of the hLH β polyclonal antiserum to hLH β cf.

The cross-reactivities of the polyclonal antisera to hLH β and to intact hLH with hLH β cf were further evaluated in an RIA using hLH β cf labeled with I¹²⁵ (Figure 10). Both polyclonal antisera clearly recognized hLH β cf. The pituitary form of hLH β cf was used in this experiment but a similar reactivity pattern should also be observed with the urinary variant of this molecule, since the monoclonal antibodies developed to the pituitary material all appear to share epitopes present on the urinary molecule.

A comparison of the concentration of hLH β cf in blood and urine was undertaken by collecting paired samples beginning on the first day of the hLH surge in urine (detected by "First Response" kit) and continuing for three subsequent days in a single subject. The collection was repeated during a subsequent cycle. Figure 11 illustrates corresponding values in blood and urine for hLH, hLH β and hLH β cf. The hLH-1 assay provided a significantly stronger signal in serum than did the hLH-2 assay. The hLH β signal appears synchronously with the intact peak in this subject in urine. However, the hLH β surge starts to grow and is detected only in the urine.

The basal level (i.e. follicular level) of hLH β cf in normally cycling women was similar to the level which was detected for male urine (see Table II). Both of these groups differ markedly from the values obtained for postmenopausal subjects which were characterized both by much higher levels and a wider range of values (Figure 8). Levels of intact hLH were low in these subjects in both

-36-

assays for hLH, but there was a substantial quantity of hLH β , perhaps reflecting dissociation of the intact molecule. Only low values of hCG β cf were detected.

5 There was no significant hLH β cf surge in blood but a
substantial hLH β cf surge in urine, indicating that urinary
hLH β cf is a product of hLH metabolic processing. The lag
time in the appearance of the fragment suggests that it may
10 be a consequence of metabolic processing by the kidney or in
some other compartment.

Two assays were used for intact hLH measurements (hLH-1 and
hLH-2. The hLH-2 assay was highly specific for the intact
hLH molecule, but occasionally produced a weak signal in
15 urinary assays. The hLH-1 assay, although less specific for
hLH, (some crossreactivity with hCG, (see Table III) but
could detect signals of greater amplitude, and had better
detection when applied to urine specimens. The hLH-2 assay
barely detected hLH in the serum of this subject but
20 detected the urinary form as well as the hLH-1 assay, which
performed equally well in both serum and urine. This
probably reflects metabolic processing of the hLH which
affects epitope presentation upon passage of blood to urine.

TABLE III
Assay Specificity and Sensitivity

Antigen	LH-1	LH-2	LH β	LH β cf	hCG β cf
hLH,%	100	100	29	1	<1
hLH β , %	<1	<1	100	1	<1
hLH β cf,%	<1	<1	<1	100	2
hCG β cf,%	2	<1	<1	<1	100
hCG,%	100	<1	<1	<1	1
hCG β ,%	31	<1	<1	1	<1
LDD*, fmol/ml	1	1.5	1.4	1	0.6

LDD* - least detectable dose

Predicting Onset Of Menopause In Perimenopausal Women. A urinary-based assay was used which measures a highly stable metabolite of luteinizing hormone which appears in the urine of all individuals but displays different daily patterns of excretion in relation to the physiological state of the individual. The immunoassays to measure the hLH beta core fragment were developed to the form of the fragment isolated from the pituitary and described above. These assays also measure the form of the molecule that appears in urine (Burger, et al., 1995). The hLH β cf is elevated in normal premenopausal women one or two days after the mid-cycle LH surge (Burger, et al., 1995). The present invention is based on measurements during the follicular phase, usually the ten day period between day one of menses and day 10. Five to ten days of daily, first morning void urine specimens were collected, starting at day one or day two of menses. The amount of hLH β cf concentration in fmole/ml was measured and normalized to creatinine (divided by creatinine concentration in mg/ml). It was determined that premenopausal patterns are easily distinguishable from postmenopausal patterns based on the simple algorithm of area under the peak when at least 5 daily measurement are performed. The average area under the peak for premenopausal women is usually 2-3 standard deviations away from the area under the peak of postmenopausal women (their

-38-

urine sampling is for 5-10 days, first morning void, at random since they do not have menstrual cycles). The test population of interest is perimenopausal women. The perimenopausal women examined exhibited a hLH β cf profile similar to the profile for premenopausal women or a hLH β cf profile similar to the profile for postmenopausal women. Two perimenopausal women with postmenopausal patterns were known to enter menopause within a year of analysis while two women showing premenopausal patterns did not enter menopause for several years. Several women were followed for a period of years.

The discrimination of the urinary hLH β cf assay is shown in Figures 12-13. These are patients whose urines were collected for 60 days as described above. Both patients were considered to be perimenopausal but both had normal regular cycles. The hLH β cf profile of patient JD is similar to the profile of postmenopausal women while the profile of patient MJU is similar to the premenopausal profile. The assay correctly predicted which patient was closer (exhibited temporal proximity) to menopause since JD, who is now postmenopausal, began to experience irregular cycles within a year of this collection, while MJU only began to experience such irregularities, several years later than JD. JD became postmenopausal within two years.

Predicting Onset of Menopause in Perimenopausal Subjects Using the Area Under The Curve Determined for hLH β cf. This experiment takes advantage of the excellent and unique assay described in detail above. The hLH β subunit, hLH β cf, which is analogous to the hCG beta core fragment in structure and by its similar appearance chiefly in urine. The assay, described in detail above, is a two-site immunoassay to the core fragment molecule which is sensitive to less than 1 fmole/ml in urine. The hLH β cf molecule appears in urine at concentrations much higher than that of hLH 1-2 days after the LH surge in normal premenopausal women. In postmenopausal women, the urinary hLH β cf appears in a

-39-

pulsatile fashion when consecutive first morning void urines are examined. The amplitude of the fluctuations in postmenopausal individuals are much greater than during the follicular phase of premenopausal individuals forming the basic design of a differentiating assay. Simply summing the area under the peak of graphs plotting day of collection versus hLH β cf in fmoles/mg Creatinine results in sets of numbers that easily distinguish premenopausal from postmenopausal subjects (see Table IV). The Lh β cf urine samples should preferably be at least 2 ml of first morning void urine. The data in Table IV suggests that in the perimenopausal group, the two subjects reflecting areas greater than 3,000 exhibit the greatest temporal proximity to menopause. In other words, of the patients presented in this experiment, the two subjects with areas greater than 3,000 are closest to menopause. Interestingly, they are still experiencing menstrual cycles; one exhibits regular cycling. The subject with an area of 344 is predicted to be temporally distant from menopause.

20

In this experiment, the perimenopausal group was defined by age. Women 43 years or older were included in this group if they were not already menopausal. Samples were taken from this group during the follicular phase for ten days where day 1 was menses. Samples taken from the menopausal group were from any ten days. Samples were taken from the premenopausal group during the follicular phase for ten days where day 1 was menses.

25

Interestingly, for these data, the mean Area value for the premenopausal group (n=13) is 237, while the mean value for the postmenopausal group (n=8) is 2267.5, a value nearly 10-fold increased as compared with the premenopausal group. Of the six perimenopausal samples, two Area values (3095 and 3735) exceed the mean Area value for the postmenopausal group; one (344) is less than twice the mean Area value for the premenopausal group; two (614 and 684) are between two and three times the mean Area value for the premenopausal

35

-40-

group; and one (849) is between three and four times the mean Area value for the premenopausal group.

Of course, mean Area value is not the only measure or method of analysis of the data, in order to determine similarity of a perimenopausal sample with the premenopausal or postmenopausal groups. Median values are also important, as is regression analysis, pattern analysis and multiplex analyses.

TABLE IV

Area under the Curve for hLH β cf Determined in Samples Taken from Subjects

Premenopause	Perimenopause	Postmenopause
190	344	2764
53	3095	4597
613	684	2501
321	614	2070
148	849	1688
73	3735	1168
251		2181
378		1171
6		
129		
603		
165		
158		

Predicting onset of menopause in perimenopausal subjects using subject-described symptoms and the area under the curve determined for hLH β cf. In this experiment, a questionnaire was used to assess if women had regular cycles and if they thought they had menopause symptoms. In this experiment, the "menopause symptoms" was the subject's subjective answer which may not truly indicate menopause

symptoms. Additionally, self-defined menopause symptoms may vary from subject to subject. Further, accurate description of symptoms may result, not from onset of menopause, but from other unidentified causes.

5 "Cycles" indicate the presence of regular menstrual cycles as described by the subject. This should be an objective measure of a change, though not necessarily an accurate measure of menopausal status for the reasons as described
10 above. Under the heading of "comments" prediction is: (1) far (indicating temporal distance from menopause by Area value); (2) closer (indicating approaching or increasing temporal proximity to menopause by Area value); (3) very close (high temporal proximity to menopause by Area value);
15 and (4) n.c. (indicating a result that is not consistent with the Area value based on a woman's report of symptoms or cycle regularity).

Collection of urine samples from the subjects and
20 measurements of hLH β cf were performed as described above. The data was plotted and area under the curve (Area) was calculated as described above. The data are presented together with the corresponding questionnaire data in Table V below:

TABLE V
Symptoms and Prediction of Onset of Menopause

Patient	Age	Symptom	Regular Cycle	Area	Comment
1	46	no	yes	737	closer
2	47	yes	no	166	n.c.
3	45	no	yes	317	far
4	48	yes	yes	26	n.c.
5	47	no	yes	48	far
6	45	yes	yes	1518	very close
7	46	no	yes	89	far
8	47	no	yes	22	far
9	47	yes	no	1518	very close
10	47	no	yes	62	far
11	43	no	yes	249	far
12	46	slight	yes	13	far
13	48	yes	yes	752	close
14	50	no	yes	866	close
15	43	no	yes	101	far
16	43	yes	no	849	close

Experimental Procedures

Hormones

hLH (AFP-4261-A), hLH β (AFP-3477A), anti-human LH-2 antisera and anti-human LH beta-1 antisera for RIA were provided by the National Hormone and Pituitary Program, NOTCHED. Standards used in the IRMA's were hLH (AFP-8270B), hLH β (AFP-3282) (all from the same source). HCG β cf were prepared as described by Birken (Birken et al., 1988; Birken et al., 1993).

-43-

Iodination of hLH β cf, hLH, hLH β , purification and iodination of monoclonal antibodies: iodination and separation of monoclonal antibodies and hormones were performed as previously described (Kovalevskaya et al., 1995).

5

Liquid phase RIA with ^{125}I -hLH β cf

The liquid phase radioimmunoassay (RIA) procedure was conducted as follows: 0.1ml serial dilutions of rabbit antiserum to hLH or hLH β in phosphate buffered saline (PBS) containing normal rabbit serum (Sigma) and 0.1% sodium azide were added to 0.2ml ^{125}I -hLH β cf (30,000 cpm) in PBS with 0.1% BSA (Sigma). The mixture was then incubated overnight at 4°C. Then 0.2ml sheep anti-rabbit serum was added and this solution was incubated overnight at 4°C. The precipitate containing radioactive hLH β cf was separated by centrifugation and ^{125}I -content determined by gamma counting (Packard Cobra).

Liquid phase RIA for hLH and hLH β

Liquid phase radioimmunoassays (RIA) were conducted as recommended in NHPP instructions. In brief, the binding buffer (buffer A) consisted of PBS supplemented with 0.1% BSA and 0.1% sodium azide. 0.1ml hLH- or hLH β -antiserum in PBS 1% normal rabbit serum was also added. Both antisera were prepared in rabbits. This solution was mixed with 0.1ml of radiolabeled hLH or hLH β (30,000-40,000 cpm) in buffer A and incubated overnight at 4°C. Then 0.2ml of a sheep anti-rabbit serum was added and mixture was incubated overnight at 4°C. The precipitate containing bound radioactive hLH β or hLH was separated by centrifugation and counted in a gamma counter.

IRMA

The methodology for the construction and validation of Immunometric assays has been fully described (O'Connor et al., 1988). Briefly, the specificity of the antibody pairs and their capacity for simultaneous binding to antigen are

-44-

determined as follows. The analytes tested for potential cross reaction with the hLH β cf monoclonal antibodies included hCG β cf, hLH (AFP 8270B), hLH free β subunit (AFP 3282B), intact hCG (CR 127) and hCG free β subunit (CR129).
5 The range of the β core LH standards was 3.9 to 1000 fmol/ml. The range of cross reactants encompassed 39 to 278000 fmol/ml, depending on the analyte.

The capture antibody was adsorbed onto the wells of
10 microtiter plates by incubating a 20 μ g/ml solution of the antibody in coating buffer (0.2 M bicarbonate, pH 9.5) overnight at 4 C. The coating antibody solution was aspirated, the plates were washed (wash solution 0.9% NaCl, 0.05% Tween 20) and blocked with a 1% solution of BSA in
15 PBS. Following incubation with the BSA solution (minimum 3 hours at room temperature) the blocking solution was removed, the wells were again washed with wash solution and 200 ml/well of the appropriate hLH β cf standards or potential cross-reacting molecules were added in phosphate buffer B
20 (0.05M phosphate with 0.1% bovine gamma globulin, 0.15M NaCl and 0.1% NaN₃). After overnight incubation at 4 C, the plates were again aspirated and washed. The 200ml (50,000 cpm - 100,000 cpm) of appropriate ¹²⁵I-labeled detection antibody (listed with double asterisks in Table 2) was added to the
25 wells which were again incubated for 24h at 4C. The tracer was aspirated, the plates washed with water, the individual well placed in glass tubes and the radioactivity determined in a Packard Cobra gamma counter. Doses were determined by interpolation from a smoothed spline transformation of the
30 data points.

In addition to hLH β cf assays, three other assays, described earlier, were used for hLH and hLH β (Krichevsky et. al., 1994) and for the hCG β cf (Krichevsky et al., 1991).

35 For the assay of urinary hLH and its metabolic forms, the following antibody pairs were employed: For intact hLH, B406*-A201**; for the hLH free beta subunit, B408*-B409**;

-45-

and for the hLH β cf B505*-B503**. Prior to assay, the urines are thawed, the pH is adjusted with 1.0M Tris (pH 9.5), 50 μ l/ml urine, centrifuged and aliquoted (200 μ l/well) into 96 well microtiter plates which had been previously coated with capture antibody and blocked with BSA. A serially diluted standard curve of the appropriate analyte (intact hLH, hLH free beta subunit or hLH β cf) is added in buffer B to the wells and the plate is incubated overnight at 4C. The assay is performed from that point identically to that described for antibody characterization.

Antibody characteristics and assay construction

The development and validation of immunometric assays for intact hLH, hLH free beta subunit (Krichevsky et al., 1994), hLH β cf (Kovalevskaya et al., 1995) have been described previously. Briefly, microtiter wells (Immulon II, Dynatech, Chantilly VA) were coated (200 μ l/well) with the appropriate, pretitered solution of the capture antibody in sodium bicarbonate buffer (pH 9.5, 0.2M) by overnight incubation at 4°C. The coating antibody solution was then aspirated, and after blocking the plates with 1% BSA in PBS (overnight 4°C) the plates washed 5 times with wash solution. Urine specimens, after pH adjustment to approximately 7.5 (1.0M TrisHCl, pH 9, 50 μ l/ml), or standards in PBS/0.1% sodium azide/0.1% bovine IgG buffer (Buffer B) and urine controls were then applied to the wells (200 μ l/well) and incubated overnight at 4°C. The wells were aspirated, washed five times with wash solution and the appropriate radioiodinated detection antibody (tracer) (50,000cpm - 100,000 cpm in buffer B) was added to the wells (200 μ l/well). After an additional overnight incubation at 4°C, the wells were aspirated, the plates washed with deionized water 5 times and the wells were separated and counted in a gamma counter (Packard Cobra). Values for the samples and controls were interpolated from a smoothed spline transformation of the standard curve.

-46-

hLH was measured by A407(capture)-B207(tracer) (hLH-1 assay) and B406-A201(hLH-2) (Krichevsky et al., 1994). HLH β was measured by the B408-B409 assay (Krichevsky et al., 1994) hLH β cf was detected by the B505-B503 assay (Kovalevskaya et al., 1995) and hCG β cf-by the B210-B108 assay (Krichevsky et al., 1991). The sensitivities of assays (least detectable dose, LDD) were calculated as plus two standard deviations (SD) of the standard 'zero'.

For hLH β cf, hCGcf, hLH β , hLH-1 and hLH-2, intra-assay coefficients of variation were 9%, 4%, 6%, 13% and 10% respectively. Interassay coefficients of variation were 9%, 10%, 15%, 21% and 10% for hLH β , hCG β cf, hLGB, hLH-1 and hLH-2 respectively.

15

Sample Collection

A) First morning void urine (FMV): Specimens were collected from normally cycling women, ranging in age from 20 to 42 years. The specimens were stored in the subject's home freezer until delivered to the laboratory.

20

B) Large scale periovulatory urine collection:

Five subjects were provided with a home ovulation detection kit ("First Response", Carter Wallace, Inc.). Starting with the first day of a positive hLH test signal, daily 24 hour urine collections were made for the succeeding seven days.

25

C) Cycles without a detectable urinary intact hLH signal:

Four subjects were selected from a population of women who recruited as normal controls for an investigation of hormone metabolism in premenstrual syndrome subjects. They were between the ages of 18-40 years, and were not pregnant or planning pregnancy. They had regular menstrual cycles and were not using any medication, drug or vitamin known to perturb the menstrual cycle.

35

D) Male urine (FMV): First morning void male urine was

-47-

collected from 11 subjects between the ages of 18-60.

E) Postmenopausal urine, large volume collection:

Postmenopausal urine was collected from one subject (age 66) by pooling daily collection urine for 40 days. 500 ml of this pool was processed in the same manner as the periovulatory urine pool.

F) Postmenopausal urine random collection: Postmenopausal urine was collected from 107 subjects enrolled in a study of baseline CA-125 levels in postmenopausal women (Westhoff et al., 1992). The women were recruited from patients at a general medical clinic or a screening mammography appointment. No woman was enrolled who was receiving treatment for any gynecological condition. The subjects ranged in age from 43 to 74 years.

G) Matched blood and urine collection: Matched blood and urine were obtained at the same time from a single person on two occasions, starting with the first day of a positive hLH test signal in urine according to "First Response" kit and continuing for a total of four days.

Characterization of urinary hLH β cf

Aliquots of the morning urine from ovulating women were assayed for hLH β cf and collections of the sequential 24 hour urines for days which tested positive were pooled, the pH adjusted to 7.5 using 1.0M Tris HCl and sodium azide (0.1%) was added. One half of this pool was filtered through a 0.45 μ membrane (Nalgene, Rochester, NY) and concentrated in an Amicon Cell using a YM-3 membrane (Amicon, Danvers, MA). The concentrate was desalted and delipidated on a Sephadex G-15 column (Pharmacia, Piscataway, NJ). The eluate was lyophilized and dissolved in 0.1M ammonium bicarbonate buffer, and half of it was gel filtered on double tandem columns of superose 12 (Pharmacia). The entire amount was used in the case of postmenopausal urine.

-48-

Column fractions containing hLH β cf immunoreactivity were pooled, lyophilized and then dissolved in 4M guanidine HCl containing 0.1% TFA (pH4). This solution (1.2ml) was applied to a Vydac C-4 Column (22 x 4.6 cm). A binary linear gradient was run. Solution A was 0.1% TFA in water, Solution B was 0.1% TFA in acetonitrile. The flow rate was 1.0ml/min; gradient 10 min 10% B to 70 min 40% B.

Pituitary hLH β cf was chromatographed under the same conditions as the urinary concentrates.

Urinary steroid metabolite assays

The solid phase microtiter plate-based ELISA's for estrone-3-glucuronide (E₁-3-G) and pregnanediol-3-glucuronide (Pd-3-G) were performed with monoclonal antibodies provided by Carter Wallace, Inc. The enzyme-conjugated steroids were provided by Dr. Bill Lasley, and the assays performed according to the procedure of Munro et al., 1991).

hLH β cf stability

Midcycle urine, encompassing the hLH urinary metabolite peaks, was collected from five subjects, pooled; pH was adjusted to 7.5 using 1.0M Tris HCl and sodium azide (0.1%) added. Aliquots of the urinary midcycle peak (endogenous urinary hLH β cf) and blank urine (B105 immunoextracted to remove hCG- and hLH-associated urinary metabolites from the urine and thus reduce the background) were stored at -80°C (control samples). Replicate samples (plus blank) were stored at 4°C, 22°C, and 37°C for extended time periods. After each time period the samples were returned to the -80°C freezer. The freeze/thaw specimens were removed from the -80°C freezer from one to five times/day and thawed either at room temperature or in a water bath at ambient temperature. After the indicated number of freeze/thaw cycles the samples were returned to the -80°C freezer. At the completion of the stability study, all of the specimens were analyzed in the same assay, in order to avoid

-49-

interassay variation.

The B105 immunoextracted urine exhibited the same blank value as buffer B.

Statistical analysis

Data were analyzed using the SigmatStat Program, version 1.01 (Jandel Corporation, San Rafael, CA). One-way analysis of variance with Bonferroni adjustment was used to evaluate stability studies. A comparison with a P-value less than 0.05 was considered significant.

Creatinine

Creatinine determinations were performed in a 96-well microtiter plate format by a procedure adapted from Taussky (Taussky, 1954).

Mass-spectrometry

Mass-spectrometry was performed on a Perceptive Biosystems Voyager DE RP instrument run in linear mode using a matrix of sinapinic acid or DHB.

Sialic acid and sulfate analysis

Sialic acid and sulfate analysis were performed using a Bionex PAD as described (Birken et al., 1996).

-50-

EXAMPLE 2: Assessing Hormone Replacement Therapy (HRT).

Clinicians caring for women must make judgements as to the ovarian state of the patient without a clear guide for classification of the patient as pre, peri or postmenopausal. Currently, decisions about estrogen replacement therapy (ERT) are usually made in response to the patient's symptoms (hot flashes, mood disorders, etc.) and chronological age rather than any objective diagnostic tests (Burger, et al., 1995; Burger, 1994a; Burger, 1994b; Hee, et al. 1993). Supplementing estradiol on an unknown background (single tests) may be hazardous to the patient. It may promote a cancer or lead to uterine hyperplasia. Detailed menstrual histories are probably the best current criteria of perimenopause (Burger, 1996; Burger, 1994b; Metcalf, 1988; Metcalf, et al. 1981b). It is possible that the patient's symptoms are associated with other underlying problems which may be overlooked if they are attributed to early menopause. The high cost and inconvenience of multiple venipunctures for a complete serum estrogen or serum LH profile of a menstrual cycle is prohibitive as a diagnostic route. There are no good markers of the effectiveness of the doses used in estrogen replacement therapy. New markers of the effectiveness of the estrogen replacement therapy will enable proper adjustment of the dosage. Monitoring estrogen therapy would benefit from the discovery of new markers of the effectiveness of the therapy. New markers of menopause are needed since symptoms may be associated with an existing disorder. Symptoms may be associated with another existing disorder. Currently, serum gonadotropins, as well as serum inhibins are markers of limited use. In addition, it is not possible to perform complete LH and FSH serum assays along with urinary steroids for one or two cycles for definitive staging of perimenopause. Further, gametogenic failure precedes estrogen failure by several years and has no good chemical marker.

-51-

A test, described herein was devised which is performed using the same daily measurements of hLH beta core fragment as described above for postmenopausal women, specifically, five consecutive days of first morning void urine were collected. Using three patients (specimens that were coded and blinded to the investigators) who received various doses of estrogen, it was determined that one woman exhibited a hLH β cf profile similar to the profile for premenopausal women. One woman exhibited a hLH β cf profile similar to the profile for postmenopausal woman and one was intermediate. This may be interpreted as meaning that one woman was not getting an adequate estrogen dose, since she remained in a postmenopausal pattern while a second woman was receiving an adequate dose since her hLH β cf profile returned to a premenopausal profile (see Figures 14A-14F).

The profile for patient LK (see Figures 14A-14B) revealed an area under the curve of 3050 before ERT and 1650 after ERT. The pre-ERT hLH β cf profile is similar to that observed for postmenopausal women. The reduction following treatment indicates that the ERT is somewhat effective. Patient LK exhibits an intermediate pattern after ERT treatment. The profile for patient VP (see Figures 14A-14B) displays an area under the curve of 1350 before ERT and 280 after ERT. This indicates ERT treatment was effective in reducing the amount of hLH β cf to an amount similar to the premenopausal pattern. The profile for patient NP (see Figures 14E-14F) revealed an area under the curve of 3200 before ERT and 3260 after ERT. This indicates that the ERT treatment was not effective in altering the amount of hLH β cf. Patient NP continues to exhibit a profile similar to the the postmenopausal profile.

-52-

EXAMPLE 3: Assessing Ovarian Function: Polycystic
Ovarian Disease.

5 Blood samples were taken from women with polycystic ovarian
disease (PCO). hLH β cf was detected in the blood of some of
these patients. Furthermore, upon treatment with GnRH a
rise in hLH β cf in the blood was measured. This could
suggest a release of core fragment from the pituitary
although a cross reaction might occur if the hLH
10 concentration is very high. Thus hLH β cf which is not
usually measureable in blood, can be detected in plasma
after ethanol fractionation.

15 When PCO patients were treated with single injections of
GnRH, Luprolite acetate (1 mg/dose), hLH β cf appeared in the
serum. Thus, hLH β cf may have two origins, one directly from
the pituitary and a second from peripheral degradation of
circulating hLH (see Table VI). Unlike normal controls,
some women with PCO have detectable hLH β core fragment in
20 serum.

TABLE VI

Patients' Serum Concentration of hLH β cf / time after GnRH treatment

pat.#	Urine.	0h	1h	2h	4h	8h	12h	24h
001a	44 ^a	0 ^b	?	4.6	12	10	14	6.8
001b	38	0	4	6	10	12	8	4.8
002	30/32 ^c	0						
003	26/26	0						
004	260/28 0	0	0	0	8	12	10	0
006	360/32 0	0	0	0	4	6	4	0
007	76/80	0	0	0	0	0	0	0
008	50/40	0						
009	240	14						

a. fmol/mg creatinine in urine;

b. fmol/ml in serum c.

These studies are further supported by work with plasmapheresis fluid. The plasma of two postmenopausal patients undergoing this treatment was tested directly and found to exhibit no measurable levels of hLH β cf. However, after ethanol fractionation of the plasma and concentration (10X), high levels of the fragment was observed. In both patients, the fractionated plasma was gel filtered and the hLH β cf immunoreactivity appeared at its expected size of 10,000 M.W. Thus, at least some of this metabolite of hLH circulates in postmenopausal women, perhaps in a form complexed to another protein and only visible after dissociation by organic solvents.

This hLH fragment may circulate in blood, unlike the homologous hCG fragment which exists at very low levels in blood. Chromatographic separation of the pituitary hLH β cf as compared to the urinary molecule with the epitope

-54-

recognized by our hLH β cf assay indicated that the urinary material eluted in a different position on reverse phase HPLC than did the pituitary form.

-55-

Example 4

Development of Markers of Menopause: Different Patterns of excretion of the hLH beta core fragment in daily urines of premenopausal as compared to postmenopausal women

Objective: As part of a long-term effort to develop new objective biochemical assays to stage women during the perimenopausal transition, the patterns of urinary excretion of a metabolite of hLH in premenopausal, perimenopausal and postmenopausal women have been examined. This metabolite is an ideal urinary analyte, highly stable, and easily measured due to its high molar content, and suffering from none of the multiple isoforms and subunit dissociation problems entailed with LH urinary measurements.

Design: The concentration of the hLH beta core fragment in 10 consecutive first morning void urine specimens from premenopausal, perimenopausal and postmenopausal women was measured. Day one of collection was the first day of menses in the cycling women.

Results: Postmenopausal women exhibited a widely fluctuating pattern of fragment excretion which is not correlated with hLH measured in urine considering the 1-2 day delay in metabolite excretion. The postmenopausal group was easily distinguished from premenopausal women based on an area-under-the-curve concentration function. Perimenopausal women displayed intermediate hLH beta core fragment concentrations some being clearly in postmenopausal ranges.

Conclusion: The pattern of excretion and concentrations of the hLH beta core fragment is significantly different between premenopausal and postmenopausal women. Perimenopausal women exhibited intermediate changes. Further study of a larger perimenopausal population

-56-

should permit development of a discriminant function to distinguish those women closest to menopause.

5 The physical, social and psychological correlates of transition of women into menopause are currently the subject of major research initiatives in woman's health.

(1). This initiative is hampered by a lack of biochemical tools that demonstrate the natural history of menopause

10 (2). Although elevated FSH concentrations during menses (day 3 of cycle is sometimes employed to confirm that a woman is close to menopause wide quantitative variations in such measurements among women and even from cycle to cycle for an individual woman limit the utility of such tests (2-7).

15 Consequently, clinical decisions for treatment of perimenopausal women today are based chiefly upon subjective symptoms rather than objective diagnostic tests. The capability to better define objective criteria for stages of the menopausal transition would be an important advance for both the research and clinical
20 settings. Objective tests would improve patient treatment based upon knowledge of where the woman was in the menopausal transition. For example, preventive therapy to avoid osteoporosis may be undertaken earlier if studies showed this problem begins before the final
25 menses.

The use of urinary assays of gonadotropin degradation products as stable, easily measured markers which may more precisely define the phases of perimenopause and
30 possibly predict the time to cessation of menstrual cycles are being explored. These degradation fragments provide the long term stability necessary in a urinary marker molecule, unlike LH itself which may dissociate into its subunits upon prolonged storage and multiple
35 freeze -thaw cycles. In addition, urinary metabolites can be measured in large scale epidemiological studies where it is not possible to collect multiple blood samples.

-57-

The hLH beta core fragment (hLH β cf), presumed to be a degradation product of circulating LH, is a highly stable metabolite in urine (8, 9). An analog of this molecule also exists in pituitary tissue, which was in fact the source of the immunogen used to develop a specific and sensitive immunometric assay for its measurement (10). The elevated urinary concentration of this molecule which occurs 1-2 days after the LH surge in normally cycling women as well as in random samples of postmenopausal urine has been previously described (8, 9). The long-term hypothesis which is being tested is that measurement of the concentration of this urinary metabolite of hLH will provide part of an objective assay to determine how far a woman is from menopause. In this report it is demonstrated that its daily pattern in postmenopausal women and the change in its quantitative and qualitative pattern from that of women still experiencing menstrual cycles.

Materials and Methods:

Subject Populations Studied:

Patient Descriptions: For the three classes of subjects studied, the following criteria of classification were used:

Premenopausal women (10 subjects were studied) were defined as 1) having regular menses with intermenses-intervals between 25 and 45 days and no missed menses or a reported change in flow in the past 12 months and not taking birth control pills. Ages of subjects were 20-42.

Perimenopausal women (18 subjects were studied) were defined as: 1) age 43 or older; 2) a history of regular menstrual cycles 25-35 days in length; 3) non-smoking status; 4) no excessive exercise (>1 hour/day) or aggressive dieting (loss of >1lb per week); 5) no diseases affecting gonadotropin or sex steroid secretion, clearance, or excretion; 6) no hormonal therapy within 3

-58-

months of the study; 7) no period of amenorrhea exceeding 3 months in the past year.

Prematurely menopausal women (4 subjects were studied) were less than 40 years of age and met criteria 3-6 above as well as the following additional criteria: 1) at least 90% normal weight for height (Metropolitan Life Tables); 2) normal menarche at age 10-15 with normal menses 25-35 days in length prior to onset of their disorder; 3) serum FSH >40 mIU/ml and estradiol less than 40 pg/ml; 4) at least 1 year of amenorrhea prior to study or no unscheduled menses while on hormone replacement therapy; 5) onset of amenorrhea prior to age 35; 6) 46, XX karyotype on 50 cells; 7) no evidence of autoimmune polyglandular failure, with normal findings of an SMA-18, CBC, negative antithyroglobulin, antimicrosomal, antimitochondrial and antiadrenal antibodies, negative ANA, and a normal 1-hour cortisol response to 250 μ g exogenous cosyntropin.

Postmenopausal women (8 subjects were studied) had menopause at age 50 or later and met criteria 2-6 for perimenopausal women, and criteria 1-4 for the prematurely menopausal women.

All participants in this study gave their informed consent prior to entry. The patients contributing samples for 30 or 60 day intervals were studied under protocols approved by the Institutional Review Board at the New Jersey Medical School. These patients have been studied earlier using other assays (11, 12). Additional patients were recruited at Columbia University and at the University of Pennsylvania each of which had their respective studies approved by their own Institutional Review Boards.

Assays:

The immunometric assay for the hLH β cf has been described in detail elsewhere (13). This assay displays intra and inter assay coefficients of variation of 10%. Earlier studies of stability of the hLH β cf demonstrated that its immunoreactivity remains unchanged after 40 freeze-thaw cycles and two weeks at 37C (8). Creatinine content of urine was determined by use of a Beckmann II creatinine analyzer or by using a modification of the method of Taussky (14) and has been previously reported (15).

LH was measured using a fluoroimmunoassay previously validated for use in urine (DELFIA; Pharmacia, Gaithersburg, MD; (15)). Glycerol preservation of the urine was essential for the maintenance of gonadotropin immunoreactivity (16), (15). The interassay coefficient of variation for the LH assay was 18% and the intra-assay CV was 8%. This assay has been demonstrated to be sensitive to 0.1 mIU/mg creatinine (15)

Statistical Analyses and Graphics: Statistical analysis was performed using Graphpad InStat (version 3.00 for Windows, Graphpad software, San Diego, CA, www.graphpad.com). Descriptive statistics of each group as well as unpaired t test with Welch correction was performed to test capability to distinguish grouped data using this program. Drawing of graphs as well as calculations of areas under the peaks were performed using Sigmaplot 4.01 for Windows (SPSS, Inc., San Rafael, CA.)

Results:**Premenopausal Pattern of hLH β cf.**

5 The premenopausal pattern of excretion of this molecule has been detailed in our earlier study (8) and displays mainly one major and broad hLH β cf peak 1-2 days after the LH surge and characterized by a higher molar concentration than hLH in urine. One set of first morning void urine specimens from a woman over 40 but still experiencing regular cycles, still exhibits a typical premenopausal pattern as shown in figure 15A. The urinary LH pattern (as measured in the earlier study of Santoro (11)) is shown in figure 15C. During the follicular phase, there are relatively small pulses of the hLH β cf but the major hLH β cf peak which follows the LH surge predominates the pattern.

Postmenopausal Pattern of Excretion of the hLH β cf

20 While hLH β cf was shown as beginning to rise in concentration on the day of the LH surge and to peak 1 or 2 days after the LH surge in urine from women with normal menstrual cycles, the hLH β cf pattern in postmenopausal urine displayed wide daily fluctuations. Figure 16 (upper panel) shows a typical postmenopausal pattern of hLH β cf measurements in first morning void urine specimens. This 60 day collection shows the large amplitude fluctuations in hLH β cf excretion. The amplitudes range between 100 and 1200 fmoles/mg creatinine and display wide fluctuations with sharp peak amplitudes every few days. These measurements were repeated again after freeze thawing several weeks later and a nearly identical pattern was obtained as shown on Figure 16A as 1st and 2^d. Figure 16B shows urinary measurements of hLH. While the LH values also fluctuate in amplitude, the LH peaks do not appear to correspond to hLH β cf peaks, considering the 1-2 day delay in expected

-61-

fragment appearance after an LH surge (see Figure 15C). Examination of women who experienced premature ovarian failure and were also considered postmenopausal resulted in a similar profile of large amplitude fluctuations as shown in figure 17 A. Figure 17B shows the urinary LH measurements which do not correspond to the LH β cf pattern neither in amplitude nor in the 1-2 day post LH peak delay observed in Figure 15.

One approach to comparing such pulsatile patterns is to calculate the area under the peaks of these curves that plot day of collection versus concentrations in fmol/mg creatinine. Ten day intervals were selected as a convenient set which could be fairly easily collected by volunteer subjects and stored frozen until samples were brought to the laboratory. When samples are analyzed from women still experiencing regular menstrual cycles, the 10 day interval collection provides a convenient starting point within the cycle and encompasses the follicular phase which most closely corresponds to the postmenopausal state of relatively low circulating steroids. Table 7 shows the area under the peaks of plots of day of collection versus the concentration of hLH β cf expressed as fmol/mg creatinine for regularly cycling women. The mean of the areas of these 10 subjects were 278 with a median area of 169. Using specimens studied earlier by Santoro (11), 60 consecutive early morning urine specimens were available from 6 postmenopausal women. Since there is no starting day for women with no cycles, we examined 10 day area data from each of these women to assess if each 10 day interval for a single woman was comparable to the other 10 day intervals from the same woman. It was found that there was not major variability among the six 10 day intervals in each of the six subjects (see Table 8). Table 8 shows the average areas under the peaks for these six consecutive 10 day collection intervals for each woman. The standard deviations and standard errors of the means

-62-

are fairly consistent showing that the data is not disparate within each subject. The mean of the areas ranged between 995-3905 with medians between 932-3134 for these postmenopausal subjects. The area data of the postmenopausal subjects differed significantly from the population of normal cycling women by the amplitude and area under the peaks of the daily fluctuations of this fragment. Since postmenopausal women vary in concentration of the hLH β cf and have no cycle start point for collection, as described earlier, in order to determine if any set of randomly collected consecutive postmenopausal areas can be distinguished from premenopausal areas, the worst case scenario was examined. The lowest 10 day area values were chosen from each of the 60 day collections of the 6 postmenopausal women shown in table 8 and compared these areas to the premenopausal areas of table 7 by independent T-test. The mean areas of the lowest 10 day collection for postmenopausal women (1594+/- 751) was significantly higher ($T_{(df=5)}=4.196$, $p<0.01$) than that for premenopausal women (277+/-215). There was no overlap in the two distributions: highest premenopausal area of 700 compared to the lowest postmenopausal area of 727.

Table VII. Ten Day Areas Under the Peak from Regularly Cycling Women

Patient Number	Age	Area
137	34	140
144	23	589
169	35	307
100	20	129
104	37	169
42	30	700
75	29	165
106	41	302
379	42	6
110	25	259

Mean: 278; S.E.M. 76; Median: 169

This data represents the areas under the peak of a plot of hLH beta core fmol/mg creatinine versus day of first morning void collections for 10 regularly cycling women.

Table VIII. Comparison of Ten Day Areas Segments from each of six 60 Day Daily Collections of First Morning Void Urines of Postmenopausal Women *

Subject	Mean	S.D.	S.E.M.	Median
1	995	220	90	932
2	2160	588	240	1987
3	3905	583	238	3934
4	2049	524	214	2125
5	3116	530	531	2878
6	1885	406	115	1042

* This data represents areas under 10 day segments (6 segments for each subject) of a 60 day plot of the concentration of the hLH β cf as fmol/mg creatinine in the first morning void urines of 6 postmenopausal women.

-64-

Perimenopausal to Postmenopausal Patterns. One overall goal of these studies is to be able to locate a subject within the menopausal transition and develop a discriminant function which would predict the time remaining before cessation of menstrual cycles. Figure 18 illustrates a woman who was classified as perimenopausal, by criteria described in the methods section, but more closely resembles our postmenopausal women. This subject did experience irregularity of cycles and mild hot flushes. She completed the transition into menopause approximately 3 years after the urine samples were collected. The urinary LH pattern shown in Figure 18C does not correspond to the hLH β cf pattern in urine (figure 418A). Table 9 shows preliminary data on 16 women classified as perimenopausal. The area data is scattered and most exhibit premenopausal areas. The women were asked about regularity of their cycles and queried about any menopausal symptoms. Of the six subjects who reported symptoms which may be associated with menopause, two exhibited high areas (>1500), two exhibited intermediate areas (>750) and two exhibited low areas (<500). Subject 2208 reported the beginning of cycle irregularity a year after an area value of 866 was determined by the 10 day sampling.

25

-65-

Table IX. Single 10 day urine collections from first day of menses of perimenopausal women (see methods for definition of perimenopausal group) with hLH β cf areas under the peak and other subject information.

5

10

15

20

25

30

35

40

Patient	Age	Symptom ?	Reg. Cycle?	Area
23	46	no	Yes	737
110	47	yes	No	166
126	45	no	Yes	317
167	48	yes	Yes	26
253	47	no	Yes	48
275	45	yes	Yes	1518
290	46	no	Yes	89
314	47	no	Yes	22
0697	47	yes	No	1518
2212	47	no	Yes	62
2202	43	no	Yes	249
2203	46	slight	Yes	13
2205	48	yes	Yes	752
2208	50	no	Yes	866
2209	43	no	Yes	101
2222	43	yes	No	849

Mean: 458; S.E.M.: 129; Median: 207

This table presents areas under the curve for plots of the day of first morning void urine collection and the concentration of the hLH β cf as fmol/mg creatinine for 10 days, with day 1 being first day of menses.

Graphic Presentation of Ten Day Urine Collections. As discussed earlier, the paradigm of collection of urine for 10 consecutive days has been applied, day one being

-66-

the first day of menses, essentially the follicular phase of the cycle. Figure 19 compares typical 10 day urine collections from a premenopausal woman (5A), a perimenopausal woman (5B) and a postmenopausal woman (5C). The most striking differences are the amplitudes of the hLH β cf spikes. Tables 7-9 display the results of this analysis in terms of comparative areas under the peaks for a variety of samples. While premenopausal and postmenopausal women can be very clearly distinguished, perimenopausal women display a gradation of such changes as would be expected.

Discussion:

The transition into the postmenopausal period is characterized by a variety of physical and psychological symptoms which are presumed to be due to the changes in their endocrine milieu consequent to ovarian failure (1, 4, 17-19). The capability to better define the location in the menopausal transition rather than a year or more after cycling has ceased would provide a means of conducting research into the relationship between serious health problems associated with menopause and the temporal aspects of these problems as related to the endocrine state of the woman. For example, it would be possible to determine if bone loss and atherosclerosis problems begin very early or late in the perimenopausal period. If it were possible to objectively assign a patient to a stage then conclusions as to when to initiate hormone therapy would rely more on an objective chemical basis. Some investigators declare that all current biochemical measurements have little predictive value during the menopausal transition due to wide variations in steroid and gonadotropin concentrations (2-5). Although FSH is usually assumed to change in circulating concentration earlier than LH in the perimenopause, a recent report shows age-related increases in LH in women in the early 40s age group (6).

-67-

Current data indicates that during some of the perimenopausal period estrogen levels are actually higher than those of young cycling women (11,2).

5 A luteinizing hormone metabolite as a possible urinary biochemical marker was focused on first since the immunometric tools have been developed to measure a stable LH metabolite in urine, namely the hLH β cf. This LH degradation product, based on the pituitary analog
10 isolated, is highly homologous to the hCG beta core fragment both in structure and stability (10). It consists of approximately half of the beta subunit held together by disulfide bridges. The immunochemically detected urinary form of the hLH β cf is stable in urine
15 for at least 2-4 weeks at room temperature if a microbial inhibitor is present and is stable indefinitely in the freezer and to at least 40 freeze-thaw cycles (8). It is a much superior urinary analyte as compared to the heterodimeric gonadotropins, such as hLH itself, which
20 may dissociate upon prolonged storage or multiple freeze thaw cycles. Measurements of urinary LH frequently suffer from problems such as wide variety of isoforms, some of which are not measured by various specific immunoassays, variable molar quantities in urine due to
25 metabolic degradation prior to excretion and instability due to subunit dissociation (8, 13). The hLH β cf as a terminal degradation product suffers from none of these limitations and should be stable for years in frozen specimens.

30 The widely fluctuating patterns of excretion of the hLH β cf as monitored by first morning void urine sampling differed from our original hypothesis that little variability would be observed in a single subject. Since
35 the hLH β cf is a metabolite of circulating LH, as shown by its appearance as a broad peak after the LH surge (see figure 16) (13), it was assumed that postmenopausal women who exhibit a high circulating concentration of LH would

-68-

exhibit a high plateau of hLH β cf excretion in urine. Essentially, the hypothesis was that the hLH β cf metabolite which takes 24 hr or more to reach its peak concentration in urine following a surge of LH would tend to represent an integration of the many small and large hourly pulses in circulating LH. Circulating LH is presumed to be taken up by a body compartment such as the kidney and released back into the circulation after proteolysis and then rapidly cleared into the urine. Instead of a plateau concentration, sharp peaks of LH core molecules appear in first morning void urines. These peaks are frequently quite independent of LH measured in the urine as shown in figure 16. The LH measurements in urine were conducted much earlier by Santoro under conditions in which LH stability during the time of measurement was demonstrated (glycerol added) (11). A number of postmenopausal urine specimens collected at random from 107 subjects had been measured earlier and it had been determined that the mean concentration of hLH β cf was 236 fmol/mg creatinine with a standard error of 35. (8). Although it appeared that there was an expected variability of hLH β cf among women since circulating hLH varies among women, it was assumed that much less variability would be observed in a single individual. The lack of correspondence between the hLH β cf measurement and immunofluorometric LH measurements was striking. The stability of LH core upon prolonged storage is excellent as detailed earlier(8, 13). Therefore, variability in core concentration due to instability is not a problem. At the present time, the reason for the pattern of excretion of hLH β cf is not known. The LH measurements observed in the peri- and postmenopausal women were irregular and erratic and differed greatly from those of the cycling midreproductive aged women. Similar irregular patterns of LH were noted in prematurely menopausal women. In the case of regularly cycling women, the correspondence was quite good in terms of a 1-2 day delay after the large LH

-69-

surge before appearance of the hLH β cf. The qualitative appearance of the patterns were essentially superimposable.

5 Several possibilities could explain these findings. Firstly, although good correspondence between serum and urine LH has been clearly demonstrated in cycling and perimenopausal (11, 15), postmenopausal women have not been subjected to the same level of scrutiny. It is possible that in non-cycling peri- and postmenopausal women that LH secretion is altered in a way that leads to a different ability to detect it in urine. Some evidence of this phenomenon using the DELFIA immunofluorometric assay has been previously published 10 (11). Sometimes LH is not detected at all in urine samples due either to an isoform which is non-reactive in the immunoassay or due to complete dissociation into subunits (8). Failure to obtain corresponding 'peaks and valleys' of hLH β cf suggest that differential clearance or processing of hLH β cf occurs relative to the intact molecule which appears to be the moiety measured by the immunometric (DELFIA) assay (15). Furthermore, positional (related to recumbency) or circadian effects may alter the pattern of LH that is secreted in the high-output states of overt ovarian failure. It appears as if the hLH β cf metabolite is sequestered in a tissue compartment and released into the circulation in sharp bursts which are rapidly cleared into the urine. The pulses of hLH β cf in the urine of postmenopausal women are much larger in amplitude than the pulses of LH measured by rapid 25 sampling techniques (every 10 minutes) in the blood of postmenopausal women (20). At any rate, hLH β cf assay appeared to have greater sensitivity to detect these erratic patterns of LH and may therefore prove to be predictive of the onset of the menopausal transition. 35

The hLH β cf excretory pattern of postmenopausal women is easily distinguished from premenopausal women. Comparing

-70-

the area under the peak for 10 day intervals, it was shown that studies of 60 day first morning daily collections of postmenopausal women's urine were fairly consistent with each other. The lowest area under the peak segments of such 10 day sampling of postmenopausal women with similar areas of premenopausal women were then compared and showed that the two groups can be very easily distinguished by such criteria. The perimenopausal group will require a larger population base in order to develop a discriminant function.

Since the hLH β cf used to produce the monoclonal antibodies that constitute our immunometric measurement system were generated to molecules purified from the pituitary and not from the urine, it is clear that these molecules exist in the pituitary and may be secreted by the pituitary. This would imply two possible origins of the hLH β cf in urine, perhaps the major component deriving from degradation of LH as it passes through the kidney, similar to the origin of the hCG beta core fragment from circulating hCG, or directly from the pituitary. If secreted directly from the pituitary, its clearance rate would be quite rapid (minutes) since the core is relatively small (10,000 Da). The hCG beta core is cleared quickly into the urine (21). It has been shown that the pituitary form of the hLH β cf is somewhat different than the urinary form based on different elution positions on reverse phase HPLC (13). However, at the present time, there is no facile means of distinguishing the presence of some hLH β cf of pituitary origin from that of urinary origin. Recent reports support a partial placental origin of the hCG β cf directly from placental tissue (22). It is conceivable that some pituitary hLH β cf may be secreted and modified in transit through the kidney to result in the different form observed on HPLC. Alternatively, LH can be accumulated in a tissue compartment and released in spurts after proteolysis to the hLH β cf.

-71-

In conclusion, the evaluation of measurement of a stable urinary gonadotropin metabolite, hLH β cf, as a marker of the transition to menopause has commenced. Preliminary data in this report demonstrate that postmenopausal women have much higher concentrations of this hLH metabolite than do premenopausal women. The metabolite also appears to be released from its tissue of origin in a broad, pulsatile manner which may also be indicative of proximity to menopause. Application of an area-under-the-peak algorithm indicated that postmenopausal patterns of this metabolite were easily discriminated from those of premenopausal women. A larger study is being undertaken to evaluate the application of this urinary marker to derive a discriminant function to distinguish women early in perimenopause from those later in the transition.

Example 5:

20

-73-

Example 6:

The expression of the urinary forms of hLH beta fragment
in various populations as assessed by a specific
5 immunoradiometric assay

Abstract

Human gonadotropins undergo metabolic transformations
10 which result in the presence of several smaller,
structurally and immunologically related forms in the
urine. For hLH, a beta core fragment (hLHbcf) has been
isolated from the pituitary and characterized. The
corresponding urinary fragment is inferred from mass
15 spectral and immunochemical analysis of
chromatographically separated urinary forms. Physico-
chemical characteristics, primarily mass spectral and
chromatographic, indicate that the pituitary and urinary
forms of hLHbcf have a different structure, probably in
20 the carbohydrate moieties. This communication
characterizes the expression of hLHbcf in the urine of
both reproductive and postreproductive age women and in
men, employing assays highly specific for the pituitary
form of the fragment. It was found that hLHbcf is the
25 predominant hLH associated molecular form in the urine
during periovulatory period, peaking over 1-3 days later
than intact hLH and reaching a concentration of about 600
fmol/mg creatinine, seven fold higher than either hLH or
hLH free beta subunit. Corresponding levels of hCGbcf
30 were less than 1% that of hLHbcf. hLHbcf cross-reaction
with some hLH or hLHb monoclonal antibodies may well
interfere with the accurate estimation of the day of the
hLH surge when urinary tests are utilized.

35 Introduction

Metabolic processing of circulating gonadotropins
includes renal excretion, presumably preceded by some

-74-

form of partial hormone degradation within the kidney as well as in other tissue compartments. A major form of urinary hCG- associated immunoreactivity is an epitope on a molecule smaller than heterodimeric hCG (Schroeder and Halter, 1983; O'Connor et al., 1994; Birken et al., 1996a). This molecule has been identified as an hCG beta core fragment (Birken et al., 1988; Blithe et al., 1988). It has been shown that in normal pregnancy, the core fragment constitutes a major mole fraction of urinary hCG excretion (Kato and Braunstein, 1988). Accumulating evidence has suggested that a similar hLH fragment appears in the urine. Iles (Iles et al., 1992) and Neven (Neven et al., 1993) demonstrated that, using polyclonal antisera raised against hCG beta core fragment (hCGbcf), immunoreactive beta core like activity could be detected in both postmenopausal women and in the periovulatory period of the normal menstrual cycle. Both of these investigative teams ascribed this immunoreactivity to an hLHbcf, which their polyclonal hCGbcf antibodies were detecting as a consequence of cross-reaction. Recently Birken (Birken et al., 1993) described the isolation and structural determination of an hLHbcf from human pituitaries. Employing this material as an immunogen, Kovalevskaya (Kovalevskaya et al., 1995) developed a panel of monoclonal antibodies with which specific immunometric assays for this molecule were developed. Although the urinary hLHbcf has not yet been isolated, and appears to have a somewhat different structure than its pituitary counterpart, its essential identity with pituitary hLHbcf is based on the observations that the urinary molecule shares at least two epitopes with the pituitary form; it has a similar size on gel chromatography and it appears in urine 1-3 days subsequent to the intact hLH surge, suggesting that it originated from the intact hLH molecule or its free beta subunit. This is the first communication in which a specific immunometric assay is employed to report the levels of expression of this new hLH molecular form in

-75-

men and women at different stages of their reproductive history.

Since urinary analyte stability, particularly for hLH and hFSH, has been reported to be a problem (Livesey et al., 1980; Livesey et al., 1983; Saketos et al. 1994), we also report on our studies concerning the thermal and freeze/thaw cycle stability of urinary hLHbcf.

Materials and Methods

Hormones

HLH (AFP-4261-A), hLHb (AFP-3477A), anti-human LH-2 antisera and anti-human LH beta-1 antisera for RIA were kindly provided by the National Hormone and Pituitary Program, NIDDKD. Standards used in the IRMA's were hLH (AFP-8270B), hLHb (AFP-3282) (all from the same source). HCGbcf and hLHbcf were prepared as described by Birken (Birken et al., 1988; Birken et al., 1993).

Iodination of hLH β cf, hLH, hLHb, and purification and iodination of monoclonal antibodies Iodination and separation of monoclonal antibodies and hormones were performed as previously described (Kovalevskaya et al., 1995).

Liquid phase RIA with ^{125}I -hLHbcf

The liquid phase RIA procedure was conducted as follows: 0.1ml serial dilutions of rabbit antiserum to hLH or hLHb in PBS containing 1% normal rabbit serum (Sigma) and 0.1% sodium azide were added to 0.2ml ^{125}I -hLHbcf (30 000 cpm) in PBS with 0.1% BSA (Sigma). The mixture was then incubated overnight at 4°C. Then 0.2ml sheep anti-rabbit serum was added and this solution was incubated overnight at 4°C. The precipitate containing bound radioactive hLH β cf was separated by centrifugation and ^{125}I -content determined by gamma counting (Packard Cobra).

Liquid phase RIA for hLH and hLHb

-76-

Liquid phase radioimmunoassays were conducted as recommended in NHPP instructions. In brief, the binding buffer (buffer A) consisted of PBS supplemented with 0.1% BSA and 0.1% sodium azide. A 0.1ml solution containing standards or unknown sample was added to 0.1ml buffer A and 0.1ml hLH- or hLHb-antiserum (both antisera were prepared in rabbits) in PBS containing 1% normal rabbit serum was also added. This solution was mixed with 0.1ml of radiolabeled hLH or hLHb (30 000-40 000 cpm) in buffer A and incubated overnight at 4°C. Then 0.2ml of a sheep anti-rabbit serum was added and mixture was incubated overnight at 4°C. The precipitate containing bound radioactive hLH β or hLH was separated by centrifugation and counted in a gamma counter.

Antibody characteristics and assay construction

The development and validation of immunometric assays for intact hLH, hLH free beta subunit (Krichevsky et al., 1994), hCGbcf (Krichevsky et al., 1991) and hLHbcf (Kovalevskaya et al., 1995) have been described previously.

Briefly, microtiter wells (Immulon II, Dynatech, Chantilly VA) were coated (200ml/well) with the appropriate, pretitered solution of the capture antibody in sodium bicarbonate buffer (pH 9.5, 0.2M) by overnight incubation at 4°C. The coating antibody solution was then aspirated, and after blocking the plates with 1% BSA in PBS (overnight 4°C) the plates were washed 5 times with deionized water. Urine specimens, after pH adjustment to approximately 7.5 (1.0M Tris HCl, pH 9, 50ml/ml), or standards in PBS/0.1% sodium azide/0.1% bovine IgG buffer (Buffer B) and urine controls were then applied to the wells (200ml/well) and incubated overnight at 4°C. The wells were aspirated, washed five times with deionized water and the appropriate radioiodinated detection antibody (tracer) was added to the wells (200ml/well). After an additional overnight

-77-

incubation at 4°C, the tracer was aspirated, the plates were washed with deionized water 5 times and the wells were separated and counted in a gamma counter (Packard Cobra). Values for the samples and controls were interpolated from a smoothed spline transformation of the standard curve.

HLH was measured by A407(capture)-B207(tracer) (hLH-1 assay) and B406-A201(hLH-2) (Krichevsky et al., 1994). HLHb was measured by the B408-B409 assay (Krichevsky et al., 1994), hLHbcf was detected by the B505-B503 assay (Kovalevskaya et al., 1995) and hCGbcf by the B210-B108 assay (Krichevsky et al., 1991). The sensitivity and specificity of these assays are detailed in Table 3. The sensitivities of assays (least detectable dose, LDD) were calculated as plus two standard deviations (SD) of the standard 'zero' (i.e. NSB).

For hLHbcf, hCGbcf, hLHb, hLH-1 and hLH-2, intra-assay coefficients of variation were 9%, 4%, 6%, 13% and 10% respectively. Interassay coefficients of variation were 9%, 10%, 15%, 21% and 10% for hLHbcf, hCGbcf, hLHb, hLH-1 and hLH-2 respectively.

Sample Collection

A) First morning void urine

These specimens were collected from 15 normally cycling women, ranging in age from 20 to 42 years. The specimens were stored in the subject's home freezer until delivered to the laboratory.

B) Large scale periovulatory urine collection

Five subjects were provided with a home ovulation detection kit ("First Response", Carter Wallace, Inc). Starting with the first day of a positive hLH test signal, daily 24 hour urine collections were made for the succeeding seven days.

-78-

C) Cycles without a detectable urinary intact hLH signal
Four subjects were selected from a population of women who were recruited as normal controls for an investigation of hormone metabolism in premenstrual syndrome subjects. They were between the ages of 18-40 years, and were not pregnant or planning pregnancy. They had regular menstrual cycles and were not using any medication, drug or vitamin known to perturb the menstrual cycle.

D) Male urine

First morning void male urine was collected from 11 subjects between the ages of 18-60.

E) Postmenopausal urine, large volume collection

Postmenopausal urine was collected from one subject (age 66) by pooling daily collection urine for 40 days. 500 ml of this pool was processed in the same manner as the periovulatory urine pool.

F) Postmenopausal urine random collection

Postmenopausal urine was collected from 107 subjects enrolled in a study of baseline CA-125 levels in postmenopausal women (Westhoff et al., 1992). The women were recruited from patients at a general medical clinic or a screening mammography appointment. No woman was enrolled who was receiving treatment for any gynecological condition. They ranged in age from 43 to 74 years.

G) Matched blood and urine collection

Matched blood and urine were obtained at the same time from a single person on two occasions, starting with the first day of a positive hLH test signal in urine according to "First Response" kit and continuing for a total of 4 days.

All collection protocols were approved by the CPMC

-79-

Institutional Review Board.

Characterization of urinary hLHbcf

5 Aliquots of the morning urine from ovulating women were
assayed for hLHbcf and collections of the sequential 24
hour urines for days which tested positive were pooled,
the pH adjusted to 7.5 using 1.0M Tris HCl and sodium
azide (0.1%) was added. One half liter of this pool was
10 filtered through in 0.45 m membrane (Nalgene, Rochester,
NY) and concentrated in an Amicon Cell using a YM-3
membrane (Amicon, Danvers, MA). The concentrate was
desalted and delipidated on a Sephadex G-15 column (40 x
2.5 cm, Pharmacia, Piscataway, NJ). The eluate was
lyophilized and dissolved in 0.1M ammonium bicarbonate
15 buffer, and half of it was gel filtered on double tandem
columns of Superose 12 (30 x 1 cm, Pharmacia). The entire
amount has been used in the case of postmenopausal urine.
Those column fractions containing hLHbcf
immunoreactivity were pooled, lyophilized and then
20 dissolved in 4M guanidine HCl containing 0.1% TFA (pH 4).
This solution (1.2ml) was applied to a Vydac C-4 Column
(22 x 4.6 cm). A binary linear gradient was run.
Solution A was 0.1% TFA in water, Solution B was 0.1%
TFA in acetonitrile. Flow rate 1.0 ml/min; gradient 10min
25 10% B to 70 min 40% B. Pituitary hLHbcf was
chromatographed under the same conditions as the urinary
concentrates.

Urinary steroid metabolite assays

30 The solid phase microtiter plate-based ELISA's for
estrone-3-glucuronide (E_1 -3-G) and pregnanediol-3-
glucuronide (Pd-3-G) were performed with monoclonal
antibodies kindly provided by Carter Wallace, Inc. The
enzyme-conjugated steroids were provided by Dr. Bill
35 Lasley, and the assays performed according to the
procedure of Munro (Munro et al., 1991).

hLHbcf stability

-80-

Midcycle urine, encompassing the hLH urinary metabolite peaks, was collected from five subjects, pooled; pH was adjusted to 7.5 using 1.0M Tris HCl and sodium azide (0.1%) added. Aliquots of the urinary midcycle peak (endogenous urinary hLHbcf) and blank urine (B105 immunoextracted to remove hCG- and hLH-associated urinary metabolites from the urine and thus reduce the background) were stored at -80°C (control samples). Replicate samples (plus blank) were stored at 4°C, 22°C, and 37°C for extended time periods. After each time period the samples were returned to the -80°C freezer. The freeze/thaw specimens were removed from the -80°C freezer from one to five times/day and thawed either at room temperature or in a water bath at ambient temperature. After the indicated number of freeze/thaw cycles the samples were returned to the -80°C freezer. At the completion of the stability study, all of the specimens were analysed in the same assay, in order to avoid interassay variation.

The B105 immunoextracted urine exhibited the same blank value as buffer B.

Statistical analysis

Data were analyzed using the SigmaStat Program, version 1.01 (Jandel Corporation, San Rafael, CA). One-way analysis of variance with Bonferroni adjustment was used to evaluate stability studies. A comparison with a *P*-value less than 0.05 was considered significant.

Creatinine

Creatinine determinations were performed in a 96-well microtiter plate format by a procedure adapted from Taussky (Taussky, 1954).

Mass spectrometry

Mass spectrometry was performed on a Perceptive

-81-

Biosystems Voyager DE RP instrument run in linear mode using a matrix of sinapinic acid or DHB.

Sialic acid and sulfate analysis

5 Sialic acid and sulfate analysis were performed using a Bionex PAD as described (Birken et al., 1996b).

Results

HLHbcf and hCGbcf in periovulatory urine

10 In the cohort of women studied (n=15), a peak of hLHbcf was observed to occur over a 3-4 day period, commencing on the day of hLH surge and reaching a maximum value of 560 (SE119) fmol/mg creatinine at 1-3 days post urinary intact hLH peak (Figure 9). A peak of hLH free beta subunit (hLHb) was observed to occur simultaneously with
15 that of the intact molecule. Although the levels of hLHb approximated those of the intact hormone, the levels of hLHbcf were several fold higher (Figure 9).

A surge of hCGbcf immunoreactivity peaked two days post
20 intact hLH, generally coincident with the peak of hLHbcf but at levels which were 1:100 of those for hLHbcf. Since the cross-reaction of the hCGbcf immunoassay with the pituitary hLHbcf was determined to be 1-2%, and since the true cross-reactivity with the urinary form is
25 unknown, it may be that the total signal detected in the hCGbcf assay is in fact due to cross-reaction with hLHbcf (Birken et al. 1996a).

The urinary hLH surge was detected by A407-B207 (hLH-1)
30 antibody configuration. Additionally, eight of the 15 cycles were rerun in a different antibody configuration assay B406-A201 (hLH-2). These assays were constructed using monoclonal antibodies to different hLH epitopes (Table 3). Both hLH-1 and hLH-2 assays gave the same day
35 of hLH surge, but the concentration of hLH in the two assays differed significantly (paired t-test, $P=0.0005$).

This observation further illustrates that the levels of

-82-

hormone detected immunologically in urine reflect the differential conservation (or stability) of hLH epitopes excreted into urine and confirm the cautionary observations of others that monoclonal antibodies may in fact be too specific to provide an accurate estimation of the level of all forms of hLH in either blood or urine (Pettersson et al., 1991; Pettersson et al., 1992; Martin-Du-Pan et al., 1994; Costagliola et al., 1994; Mitchell et al., 1995; Barbe et al., 1995; Pettersson and Soderholm, 1991).

All cycles were characterized by irregular pulsations of hLHbcf. The basal level of hLHbcf in 10 patients during first 10 days of the follicular phase (100 samples) was 32 (SE 4) fmol/mg creatinine, with a wide range of concentrations, reflecting the spikes of hLHbcf occurring before the periovulatory surge of hLHbcf (Figure 10).

HLHbcf in subjects without a detectable rise in periovulatory intact hLH

Examination of daily first morning urines from four women in which the hLH periovulatory surge was minimal or undetectable, as measured by either of our intact hLH assays, indicated that ovulation occurred as judged by the inversion of the urinary estrogen/progesterone metabolite ratio (Baird et al., 1991). Data from two of the four women are presented in Figure 7a-7d. Evidence from the urinary steroids that ovulation occurred suggested that one or more of the following occurred. The intact hormone may have been completely cleared by an alternative pathway. The alternative pathway would be clearance through the liver, which has receptors for asialoglycoproteins and sulfated glycoproteins (Flete et al., 1991; Weiss and Ashwell, 1989; Steer and Ashwell, 1986; Kawasaki and Ashwell, 1976). The intact hormone may have dissociated completely into subunits or been totally degraded into fragments prior to excretion, as is the

-83-

case with hCG, i.e. administration of the intact hCG molecule to either men or non-pregnant women results in the appearance of hCGbcf in the urine (Nisula et al., 1989). Finally, the antibodies used in these measurements, which were raised to the pituitary form of hLH, may have failed to recognize the urinary isoform of hLH present in the sample. That the lack of evidence for intact hLH was not a consequence of these subjects producing an isoform of hLH which was not recognized by these antibody combinations was supported by the fact that a clear hLH peak was found in other cycles tested from these subjects (data not presented).

These cycles however were characterized by the presence of a periovulatory peak of hLHb and a substantial secretion of hLHbcf within the expected time interval (Figure 7a-7d).

HLHbcf expression in the urine of postmenopausal women
The levels of intact hLH, hLHb, hLHbcf, and hCGbcf were evaluated in a total of 107 healthy postmenopausal women (Figure 8). The mean concentration of hLHbcf for the 107 postmenopausal women was 236 (SE 35) fmol/mg creatinine.

HLHbcf expression in the urine of males
Urines collected from eleven normal males (age 20-60) yield a value of 41 (SE 13) fmol/mg creatinine.

Comparison of hLH or hLHb measurement in urine using IRMA and RIA

hLH and hLHb were measured in urine using IRMA's incorporating specific monoclonal antibodies (Figure 9 A) and by RIA (Figure 9B), using polyclonal antisera directed against either intact hLH or hLHb, supplied by the National Hormone and Pituitary Program, NIDDKD. The RIA reagents were designed for serum assays and usually clearly provide a single day pre-ovulatory elevation of

-84-

both hLH and occasionally hLHb in blood.

When these same reagents are employed for hLH or hLHb measurement in urine however, a broad peak for either hormone was obtained. These observations can be explained by the presence of hLHbcf in the urine (Figure 9A). If panels A and B are compared, it is apparent that the day of maximum hLHb by IRMA is different from the RIA value, probably due to the greater cross-reactivity of the hLHb polyclonal antiserum to hLHbcf.

The cross-reactivities of the polyclonal antisera to hLHb and to intact hLH with hLHbcf were further evaluated in an RIA using hLHbcf labeled with I-125 (Figure 10). Both polyclonal antisera clearly recognized hLHbcf. The pituitary form of hLHbcf was used in this experiment but a similar reactivity pattern should also be observed with the urinary variant of this molecule, since the monoclonal antibodies developed to the pituitary material all appear to share epitopes present on the urinary molecule.

HLHbcf in blood and urine.

A comparison of the concentration of hLHbcf in blood and urine was undertaken by collecting paired samples beginning on the first day of the hLH surge in urine (detected by "First Response" kit) and continuing for three subsequent days in a single subject. The collection was repeated during a subsequent cycle. Figure 11 illustrates corresponding values in blood and urine for hLH, hLHb, and hLHbcf. The hLH-1 assay provided a significantly stronger signal in serum than did the hLH-2 assay. The hLHb signal appears synchronously with the intact peak in this subject in urine. However, the hLHbcf surge commences a day later and is detected only in the urine.

-85-

HPLC analysis of hLHbcf of pituitary and urinary origins

Analysis of urine fractions after gel filtration on the Superose 12 column using the B505-B503 assay indicated that all hLHbcf activity appeared in one low molecular weight peak (10 000 Da). Upon reverse phase chromatography of the gel filtered hLHbcf-containing pooled fractions on a Vydac C-4 column, the elution position of both periovulatory and postmenopausal hLHbcf immunoreactivity were identical, while that of the pituitary-derived material appeared 4 fractions later (Figure 2). This indicates that the structure of the pituitary-derived hLHbcf is likely to be different from the material present in the urine of both pre and postmenopausal women and that the urinary form of the hLHbcf is substantially the same in women of any age.

Mass spectrometric analysis of the pituitary hLHbcf

The pituitary form of hLHbcf was the immunogen for the antibodies used in these studies and was our reference standard. Understanding how its structure may differ from the urinary form being measured is important. The difference in reverse phase elution profile of the pituitary and urinary forms of the hLH β cf led us to explore such differences in structure between the pituitary and urinary forms of this molecule. We have not yet isolated the urinary form and so, concentrated on the pituitary isoform. We subjected the pituitary material to reduction and carboxymethylation (RCM) and separated the constituent polypeptide chains by reverse phase HPLC as described earlier for the hCG β cf (Birken et al., 1988). A combination of Edman amino terminal sequence analysis and mass spectrometry permitted unequivocal assignment of the constituent non-glycosylated peptide chains of the pituitary hLH β cf: one RCM chain began at residue 55, as reported earlier (Birken et al., 1993), but was measured as 4 546 Da by mass spectrometry indicating that it terminates at residue 93, CYS. This polypeptide has a theoretical mass

-86-

of 4 544.83 Da for the RCM form measured. The second non-glycosylated RCM peptide exhibited an amino terminus starting at residue 49 and a size of 5188 Da which corresponds again with a COOH-terminus of CYS 93 with a theoretical mass of 5190 Da. This is in sharp contrast to the structure of the hCGb β cf which does not include CYS 93. The glycosylated peptide, previously determined to be residues 6-40, was not subjected to mass spectrometry because of its carbohydrate heterogeneity and difficulty in isolation of its RCM form. Mass spectrometry was also performed on the native pituitary form of the hLH β cf as compared to the hCG β cf and both displayed similar sizes in the range of 9 000-10 000 Da. Theoretical calculation of the mass of each fragment indicates that both should be about 10 000 Da only if the hLH β cf single carbohydrate chain is essentially intact while the two carbohydrate groups of the hCG β cf are known to be trimmed down to the mannose cores (Blithe et al., 1988): hLH β cf is composed of 6-40 (3927 Da) + 49-93 (4896 Da) or + 55-93 (4249 Da) +full carbohydrate group with sulfate (2093 Da). The theoretical sizes of the hLH β cf are 10 916 Da for the form with the longer non-glycosylated peptide and 10 269 Da for the form with the shorter peptide. The hCG β cf is theoretically 10 347 Da. The actual mass spectrometry results yielded slightly smaller forms of both fragments but proved that the pituitary hLH β cf is likely to contain close to a complete carbohydrate group and not the trimmed down groups of the urinary hCG β cf. In fact, the hLHb β cf was predominantly one broad peak on mass-spectrometry while the hCGb β cf appears as two distinct broad peaks, reflecting variation in trimming of its carbohydrate group. Further evidence that the pituitary hLH β cf contains a carbohydrate group similar to its parent hLH β subunit was provided by the sialic and sulfate analysis which indicated that both were present in the core. Therefore, we can conclude that within the pituitary, proteolytic enzymes exist to produce the hLH β cf, but glycosidases are not active in this

-87-

metabolism as they are in the case of the hCGbcf. However, the different HPLC position of the urinary form of this molecule may be due to such carbohydrate modification. Definitive proof of the structure of the urinary form of the hLH β cf awaits its isolation.

Stability of urinary hLHbcf

The results obtained from the repeated freeze/thaw cycles indicated no statistically significant change from control for up to 40 freeze/thaw cycles ($P=0.214$). There was no statistically significant change from control in immunodetectable hLHbcf at either 4°C or room temperature for up for 29 days. At 37°C, the molecule was stable for 14 days but showed a statistically reliable change after 29 days ($P<0.05$).

Discussion

There is a considerable literature documenting the difficulty in obtaining accurate measurements, or even detecting at all, circulating hLH by immunoassay, although normal levels may be detected by bioassay in the same subjects (Pettersson et al., 1991; Martin-Du-Pan et al., 1994; Barbe et al., 1995; Pettersson and Soderholm, 1991). The causes of this phenomenon are thought to include genetic variants of the hLH molecule, leading to loss of expression of an epitope, or to the well documented existence of multiple circulating isoforms of hLH, which may have differential recognition by the monoclonal antibodies employed in the assay, as is the case with nicking of the hCG beta subunit, which results in nearly complete ablation of binding to many monoclonal antibodies specific for the intact hCG molecule.

An analogous situation can exist in urine, in cases in which antibodies that are used for hLH detection in urine cross-react with free beta subunit and/or hLHbcf. This cross-reactivity results in obscuring the real hLH surge, even when urinary steroid measurements indicate that ovulation has occurred (Wilcox et al., 1987).

-88-

Although hLHbcf, a stable hLH related molecule, is not capable of accurately segmenting the menstrual cycle because of its variable day peak occurrence, nevertheless it appears capable of confirming that the midcycle surge of hLH has in fact occurred.

This communication describes the behavior of hLHbcf, a molecule presumably derived from hLH free beta subunit, which we show to be present in both men and women, sometimes at high levels, and describes how it can confound the interpretation of hLH measurements in urine.

In a first publication concerning pituitary hLHbcf antibodies a large peak of immunoreactivity in urine which followed the hLH surge by 1-3 days was reported (Kovalevskaya et al., 1995). It was observed that monoclonal antibodies to pituitary hLHbcf shared at least 2 epitopes with the analogous protein in urine. This immunologically similar urinary molecule has been called urinary hLHbcf.

In the present study 15 cycles of normally ovulating women have been investigated. Data presented in Figure 9 show the position and concentration of urinary hLHbcf as compared with the appearance of hLH and hLHb in the urine. Additionally we measured hCGbcf, because the first evidence of hLHbcf had been obtained using a polyclonal antibody with primary specificity to hCGbcf (Iles et al., 1992; Neven et al., 1993). Using monoclonal antibodies specific to hCGbcf, we found that there is very low peak of hCGbcf exactly coincident with hLHbcf (Figure 9). This signal may be accounted for by the 1-2% hLHbcf cross-reactivity in the assay for hCGbcf (Birken et al., 1996a). Antibodies to hCGbcf which were used by Neven (Neven et al., 1993) and Iles (Iles et al., 1992) cross-react with hLHbcf to an extent which allowed these investigators to detect hLHbcf. The lag time between the appearance of intact hLH or hLHb and hLHbcf

(D12)

WO 99/39202

PCT/US99/02279

-89-

suggests that, analogously with hCGbcf, hLHbcf is a degradation product of the intact hormone or of its free beta subunit.

5 Irregular pulsations of urine hLHbcf outside of the main
periovulatory surge (Figure 10) probably reflect spikes
of hLH in blood, which are a consequence of the pulsatile
release of GnRH (Knobil, 1988; Van Dielen and De Koning,
1995; Shoham et al., 1995). Spikes of hLH are also
10 observed in urine, but at a much lower amplitude, than
those of hLHbcf.

Problems associated with the detection of a discrete hLH
surge in urine have been reported by Edwards (Edwards et
15 al., 1980). They found an intact hLH surge in 68/79
patients employing a hemagglutination assay and
confirming in some cases with a hLH radioimmunoassay. In
eleven cases a satisfactory hLH surge was not obtained.
These investigators also noted a diurnal variation in the
20 timing of the hLH surge, demonstrating that an
inadequately timed collection protocol might be
implicated in this difficulty. In the course of the
present investigation, we also observed several cycles
which did not produce a detectable intact hLH signal even
25 though urinary steroid profiles indicated that ovulation
had occurred. Two representative cycles are presented in
Figure 7a-7d. They illustrate the same pattern of hLHbcf
as seen in cycles with a measurable intact hLH value.
This surge commenced on the day following ovulation as
30 judged by urinary steroid metabolites (Baird et al.,
1991), and it peaked over the succeeding one to three
days indicating that a normal midcycle surge of intact
hLH can be confirmed by urinary hLHbcf measurements. Our
results suggest that an assay incorporating the
35 detection of all three urinary analytes would provide the
most sensitive detection of periovulatory hLH. However,
although hLHb is most often observed to peak coincident
with the intact molecule (Figure 9), it appears that it

-90-

can occasionally occur one day earlier (Figure 8 in Kovalevskaya et al., 1995). On the other hand, hLHbcf, usually peaked over 1-3 days later than the intact molecule (Figure 5) and this midcycle peak of hLHbcf has been detected in all four cycles in which there was undetectable intact hLH in the urine (Figure 7). The intact hormone may have been completely cleared by an alternative pathway. The alternative pathway would be clearance through the liver, which has receptors for asialoglycoproteins and sulphated glycoproteins (Kawasaki and Ashwell, 1976; Steer and Ashwell, 1986; Weiss and Ashwell, 1989; Flete et al., 1991). The intact hormone may have dissociated completely into subunits or have been totally degraded into fragment prior to excretion as is the case with HCG, i.e. administration of the intact HCG molecule to either men or non-pregnant women results in the appearance of HCG β cf in the urine (Nisula et al., 1989). Finally, the antibodies used in these measurements, which were raised to the pituitary form of LH, may have failed to recognize the urinary isoform of LH present in the sample.

Some further insight into this issue is provided by the comparison of hormone profiles in blood and urine for two cycles from the same patient (one cycle is presented in Figure 11). Although our lack of an adequate number of serum samples did not permit us to confirm the synchrony of serum and urine hLH secretion as reported by Cano and Aliada (Cano et al., 1995), our data is nevertheless supportive of their observation that intact hLH in blood and urine peak very nearly simultaneously.

The basal level (i.e. follicular level) of hLHbcf in normally cycling women was similar to the level which we obtained for male urine (Table 2). Both of these groups differ markedly from the values obtained for postmenopausal subjects which were characterized both by much higher levels and a wider range of values (Figure

- 91 -

8). Levels of intact hLH were low in these subjects in both assays for hLH, but there was a substantial quantity of hLHb, perhaps reflecting dissociation of the intact molecule. Only low values of hCGbcf were detected.

5

There was no significant hLHbcf surge in blood but a substantial hLHbcf surge in urine, supporting the hypothesis that urinary hLHbcf is a product of hLH metabolic processing. The lag time in the appearance of the fragment suggests that it may be a consequence of metabolic processing by the kidney or in some other compartment.

10

We chose to use two assays for intact hLH measurements (hLH-1 and hLH-2) because, although the hLH-2 assay was highly specific for the intact hLH molecule, it occasionally produced a weak signal in urinary assays. The hLH-1 assay, although less specific for hLH, (some crossreactivity with hCG, Table 3) had a tendency to detect signals of greater amplitude, with a better incidence of detection when applied to urine specimens. Incidentally, the hLH-2 assay barely detected hLH in the serum of this subject but detected the urinary form as well as the hLH-1 assay, which performed equally well in both serum and urine. The above observations probably reflect metabolic processing of the hLH which affects epitope presentation upon passage from blood to urine.

15

20

25

Another issue is the structure of the urinary and pituitary forms of hLHbcf. Are they identical or does the urinary variant, presumably arising from the intact hormone, differ in structure? The ultimate answer awaits the isolation and complete sequence and carbohydrate analysis of the urinary form. Although both the pituitary and urinary forms appear to have the same molecular size by gel filtration, on reverse phase HPLC analysis the isoforms differ in their hydrophobicity, with the urinary fragment being more hydrophilic. In contrast, urinary

30

35

forms of hLHbcf molecules from either pre- or postmenopausal urine concentrates are closely related in structure, as evidenced by identical elution times from the Vydac C-4 column (Figure). Additional structural studies of the pituitary form using a combination of mass-spectrometry and ion chromatography indicate that the pituitary hLHbcf resembles its parent hLH β in its carbohydrate moiety. This contrasts to the structure of the hCG β cf which has carbohydrate moieties trimmed to their mannose cores. Mass spectrometric analysis indicates that pituitary hLH β cf displays one peak on mass-spectrometry of about 10 000 Da similar to one of the two peaks of the hCG β cf which average 10 000 Da and 9000 Da respectively. The hCGbcf usually displays two bands on non-reduced PAGE which correspond with the two broad peaks observed on mass specrometry (Birken et al., 1988).

Livesey (Livesey et al., 1980; Livesey et al., 1983), Saketos (Saketos et al., 1994) and Kesner (Kesner et al., 1995), among others have all reported significant loss of urinary hLH or hFSH immunoreactivity upon prolonged frozen storage without addition of the cryoprotectant glycerol. Kesner determined that BSA also improved urinary analyte stability for both gonadotropins and urinary steroid metabolites in frozen storage (Kesner et al., 1995). These investigators also determined that both hLH and hFSH were essentially stable for up to two weeks at 4°C, with bacteriostatic additives having no consistent preservative effect. An investigation by de Medeiros concerning the stability of hCGbcf determined that this molecule was stable under a variety of conditions, including extended storage at room temperature, frozen storage, and repeated freeze/thaw cycles (de Medeiros et al., 1991). Again, preservatives, including protease inhibitors, did not affect immunological stability.

Analogous to hCGbcf, with which hLHbcf shares extensive structural homology, endogenous urinary hLHbcf has remarkable epitope stability, especially where contrasted with reports detailing the lack of stability during storage of the parent hLH molecule (Saketos et al., 1994; Livesey et al., 1980; Livesey et al., 1983; Kesner et al., 1995).

There are reports that measurement of the periovulatory surge of hLH in urine instead of blood leads either to errors in the assignment of the day of ovulation or to the inability to detect the surge at all (Kesner et al., 1992; Kesner et al., 1997). The identification of hLHbcf has suggested a possible source of these difficulties. The ambiguity in interpretation of different assay formats for hLH in urine is illustrated in (Figure 9). Panel A shows the results obtained when IRMA's are used to measure hLH, hLHb, hLHbcf and hCGbcf. As expected, both assays for intact hLH plus the assay for hLH free beta subunit all produce a synchronous peak for their respective analytes. The immunoreactive hLHbcf peaks 1-3 days later and declines over several succeeding days. A small peak of hCGbcf is also evident under the hLHbcf, but most, if not all, of this signal may be ascribed to assay crossreactivity. A different profile is produced when the same urine specimens are analyzed by a polyclonal RIA assay for blood measurements provided by the NHPP (Figure 9B). Although this assay produces a very satisfactory blood hLH and hLHb profile, because hLHbcf is not detected in significant amounts in blood, the results are less clear when applied to urine. The intact hLH surge now extends over several days (see also similar urinary hLH profiles in ref. (Kesner et al., 1992; Kesner et al., 1997) as examples), as does hLHb, after a two day lag time. This likely indicates that the polyclonal antisera to hLH and hLHb recognize urinary hLHbcf, suggesting that cross reactivity can lead to an incorrect assignment of the day of ovulation. Direct

- 94 -

tests with ^{125}I -hLHbcf indicate that both polyclonal antisera to hLH and hLHb cross react with hLHbcf in an RIA format (Figure 10). These results demonstrate that such cross-reactivity can lead to an incorrect assignment of the day of ovulation. This problem would not be encountered with these assays as long as their use was restricted measurements in blood, since there is little or no hLHbcf present in this medium.

The data illustrate a potential risk associated with the use of ovulation test kits designed for personal use. Should the antibodies used in their construction detect hormone fragments in addition to the intact molecule the test results could be ambiguous and misleading.

REFERENCES

- Birken, S., E. G. Armstrong, M. A. Kolks, L. A. Cole, G. M. Agosto, A. Krichevsky, J. L. Vaitukaitis, and R. E. Canfield. 1988. Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine. *Endocrinology* 123:572-583.
- Birken, S., Y. Maydelman, M. A. Gawinowicz, A. Pound, Y. Liu, and A. S. Hartree. 1996. Isolation and characterization of human pituitary chorionic gonadotropin. *Endocrinology* 137:1402-1411.
- Birken, S., Y. Chen, M. A. Gawinowicz, J. W. Lustbader, S. Pollak, G. Agosto, R. Buck, and J. O'Connor. 1993a. Separation of nicked human chorionic gonadotropin (hCG), intact hCG, and hCG beta fragment from standard reference preparations and raw urine samples. *Endocrinology* 133:1390-1397.

Birken, S., M. A. Gawinowicz, A. Kardana, and L. A. Cole. 1991. The heterogeneity of human chorionic gonadotropin

- (hCG). II. Characteristics and origins of nicks in hCG reference standards. *Endocrinology* 129:1551-1558.
- 5 Birken, S., Y. Chen, M. A. Gawinowicz, G. M. Agosto, R. E. Canfield, and A. S. Hartree. 1993b. Structure and significance of human luteinizing hormone-beta core fragment purified from human pituitary extracts. *Endocrinology* 133:985-989.
- 10 Blithe, D. L., Akar, AH, Wehmann, RE and Nisula, BC. (1988) Purification of beta-core fragment from pregnancy urine and demonstration that its carbohydrate moieties differ from those of native human chorionic gonadotropin-beta. *Endocrinology* 122:173-180.
- 15 Burger, H. G. 1994b. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition--an analysis of FSH, oestradiol and inhibin. [Review]. *Eur. J. Endocrinol.* 130:38-42.
- 20 Burger, H. G. 1994a. The menopause: when it is all over or is it?. [Review]. *Aust. N. Z. J. Obstet. Gynaecol.* 34:293-295.
- 25 Burger, H. G., E. C. Dudley, J. L. Hopper, J. M. Shelley, A. Green, A. Smith, L. Dennerstein, and C. Morse. 1995. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. *J. Clin. Endocrinol. Metab.* 80:3537-3545.
- 30 Burger, H. G. 1996. The endocrinology of the menopause. [Review]. *Maturitas* 23:129-136.
- 35 Burger, H. G., P. G. Farnworth, J. K. Findlay, C. J. Gurusinghe, D. L. Healy, P. Marners, A. Mason, and D. M. Robertson. 1995. Aspects of current and future inhibin

-96-

research. [Review]. *Reprod. Fertil. Dev.* 7:997-1002.

Cole LA, Schwartz PE, Wang YX 1988b. *Gynecol Oncol* 31:82-90

5

Cole LA, Wang Y, Elliot M, Latef M, Chambers JT, Chambers SK, Schwartz PE 1988a. *Cancer Res* 48:1356-1360

10

Cole LA, Nam JH, Chambers JT, Schwartz PE 1990 *Gynecol Oncol* 36:391-394

de Medeiros, S. F., F. Amato, and R. J. Norman. 1991. Stability of immunoreactive beta-core fragment of hCG. *Obstet. Gynecol.* 77:53-59.

15

Hee, J., J. MacNaughton, M. Bangah, and H. G. Burger. 1993. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. *Maturitas* 18:9-20.

20

Iles, R. K., C. L. Lee, I. Howes, S. Davies, R. Edwards, and T. Chard. 1992. Immunoreactive beta-core-like material in normal postmenopausal urine: human chorionic gonadotrophin or LH origin? Evidence for the existence of LH core. *J. Endocrinol.* 133:459-466.

25

Kato Y. and Braunstein G.D. (1988) Beta-core fragment is a major form of immunoreactive urinary chorionic gonadotropin in human pregnancy. *J. Clin. Endocrinol. Metab.* 66:1197-1201.

30

Kovalevskaya, G., S. Birken, J. O'Connor, J. Schlatterer, Y. Maydelman, and R. Canfield. 1995. HLH beta core fragment immunoreactivity in the urine of ovulating women: a sensitive and specific immunometric assay for its detection. *Endocrine* 3:881-887.

35

- 5 Krichevsky, A., S. Birken, J. O'Connor, K. Bikel, J. Schlatterer, C. Yi, G. Agosto, and R. Canfield. 1991. Development and characterization of a new, highly specific antibody to the human chorionic gonadotropin-beta fragment. *Endocrinology* 128:1255-1264.
- 10 Krichevsky A, Birken S, O'Connor JF, Bikel K, Schlatterer JP and Canfield, R.E. (1994) The development of a panel of monoclonal antibodies to human luteinizing hormone and its application to immunological mapping and two-site assays. *Endocrine* 2: 511-520
- 15 Lee, C. L., R. K. Iles, J. H. Shepherd, C. N. Hudson, and T. Chard. 1991. The purification and development of a radioimmunoassay for beta-core fragment of human chorionic gonadotrophin in urine: application as a marker of gynaecological cancer in premenopausal and postmenopausal women. *J. Endocrinol.* 130:481-489.
- 20 Metcalf, M. G., R. A. Donald, and J. H. Livesey. 1981. Classification of menstrual cycles in pre- and perimenopausal women. *J. Endocrinol.* 91:1-10.
- 25 Metcalf, M. G., R. A. Donald, and J. H. Livesey. 1982. Pituitary-ovarian function before, during and after the menopause: a longitudinal study. *Clin. Endocrinol. (Oxf)*. 17:489-494.
- 30 Metcalf, M. G. 1979. Incidence of ovulatory cycles in women approaching the menopause. *J. Biosoc. Sci.* 11:39-48.
- 35 Metcalf, M. G., R. A. Donald, and J. H. Livesey. 1981. Pituitary-ovarian function in normal women during the menopausal transition. *Clin. Endocrinol. (Oxf)*. 14:245-255.

-98-

- Metcalfe, M. G. 1988. The approach of menopause: a New Zealand study. *N. Z. Med. J.* 101:103-106.
- 5 Metcalfe, M. G. and R. A. Donald. 1979. Fluctuating ovarian function in a perimenopausal women. *N. Z. Med. J.* 89:45-47.
- 10 Neven, P., R. K. Iles, C. L. Lee, C. N. Hudson, J. H. Shepherd, and T. Chard. 1993. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders. *Cancer* 71:4124-4130.
- 15 Neven, P., R. K. Iles, I. Howes, K. Sharma, J. H. Shepherd, R. Edwards, W. P. Collins, and T. Chard. 1993. Substantial urinary concentrations of material resembling beta-core fragment of chorionic gonadotropin beta-subunit in mid-menstrual cycle. *Clin. Chem.* 39:1857-1860.
- 20 O'Connor, J. F., J. P. Schlatterer, S. Birken, A. Krichevsky, E. G. Armstrong, D. McMahon, and R. E. Canfield. 1988. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies. *Cancer Res.* 48:1361-1366.
- 25 O'Connor, J. F., S. Birken, J. W. Lustbader, A. Krichevsky, Y. Chen, and R. E. Canfield. 1994. Recent advances in the chemistry and immunochemistry of human chorionic gonadotropin: impact on clinical measurements. [Review]. *Endocr. Rev.* 15:650-683.
- 30 Santoro, N., J. R. Brown, T. Adel, and J. H. Skurnick. 1996. Characterization of reproductive hormonal dynamics in the perimenopause. *J. Clin. Endocrinol. Metab.* 81:1495-1501.

-99-

Schroeder, H.R. and Halter, C.M. (1983) Specificity of human beta-choriogonadotropin assays for the hormone and for an immunoreactive fragment present in urine during normal pregnancy.

5 *Clinical Chemistry*. 29:667-671.

Stenman, U. H., J. M. Bidart, S. Birken, K. Mann, B. Nisula, and J. O'Connor. 1993. Standardization of protein immunoprocures. Choriogonadotropin (CG). *Scand. J. Clin. Lab. Invest. Suppl.* 216:42-78.

References For Example 4

- 15 1. Monjan AA, Bellino FL, Ory MG, Sherman S, Weiss S. Conference on menopause. Research recommendations. *Exp.Gerontol.* 1994;29:525-528.
2. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. *Endocr.Rev.* 1998;19:397-428.
- 20 3. Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition--an analysis of FSH, oestradiol and inhibin. *Eur.J.Endocrinol.* 1994;130:38-42.
- 25 4. Burger HG. The endocrinology of the menopause. *Maturitas* 1996;23:129-136.
5. Stellato RK, Crawford SL, McKinlay SM, Longcope C. Can Follicle-Stimulating Hormone Status Be Used To Define Menopausal Status? *Endocrine Practice* 1998;4:137-141.
- 30 6. Reame NE, Kelche RP, Beitins IZ, Yu MY, Zawacki CM, Padmanabhan V. Age effects of follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women.

-100-

J Clin Endocrinol.Metab. 1996;81:1512-1518.

- 5 7. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103-113.
- 10 8. O'Connor JF, Kovalevskaya G, Birken S, et al. The expression of the urinary forms of human luteinizing hormone beta fragment in various populations as assessed by a specific immunoradiometric assay. Hum.Reprod. 1998;13:826-835.
9. Birken S, Kovalevskaya G, O'Connor J. Metabolism of hCG and hLH to multiple urinary forms. Mol.Cell Endocrinol. 1996;125:121-131.
- 15 10. Birken S, Chen Y, Gawinowicz MA, Agosto GM, Canfield RE, Hartree AS. Structure and significance of human luteinizing hormone-beta core fragment purified from human pituitary extracts. Endocrinology 1993;133:985-989.
- 20 11. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J.Clin.Endocrinol.Metab. 1996;81:1495-1501.
- 25 12. Brown JR, Skurnick JH, Sharma N, Adel T, Santoro N. Frequent intermittent ovarian function in women with premature menopause: a longitudinal study. Endocrine J 1993;1:467-474.
- 30 13. Kovalevskaya G, Birken S, O'Connor J, Schlatterer JP, Maydelman Y, Canfield RE. HLH β core fragment immunoreactivity in the urine of ovulating women : a sensitive and specific immunometric assay for its detection. Endocrine 1995;3:881-887.

-101-

14. Taussky HH. A microcolorimetric determination of creatinine in urine by the Jaffe reaction. J Biol Chem 1954;208:853-861.
- 5 15. Saketos M, Sharma N, Adel T, Raguwanshi M, Santoro N. Utility of time-resolved fluorescent immunoassay technique for urinary gonadotropin measurement. Clin Chem 1994;40:749-753.
- 10 16. Livesey JH, Roud HK, Metcalf MG, Donald RA. Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine. J.Endocrinol. 1983;98:381-384.
- 15 17. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet.Gynecol. 1996;88:437-442.
18. Hegde BM. Change of life--menopause. J.Indian Med.Assoc. 1995;93:460-461.
19. Metcalf MG. The approach of menopause: a New Zealand study. N.Z.Med.J. 1988;101:103-106.
- 20 20. Santoro N, Banwell T, Tortoriello D, Lieman H, Adel T, Skurnick J. Effects of aging and gonadal failure on the hypothalamic-pituitary axis in women. Am.J Obstet.Gynecol. 1998;178:732-741.
- 25 21. Wehmann RE, Blithe DL, Flack MR, Nisula BC. Metabolic clearance rate and urinary clearance of purified beta-core. J.Clin.Endocrinol.Metab. 1989;69:510-517.
- 30 22. Udagawa A, Okamoto T, Nomura S, Matsuo K, Suzuki H, Mizutani S. Human chorionic gonadotropin β -core fragment is present in the human placenta. Mol.Cell.Endocrinol. 1998;139:171-178.

-102-

References for Example 6

5 Baird, D.D., Weinberg, C.R., Wilcox, A.J., McConnaughey, D.R. and Musey, P.I. (1991) Using the ratio of urinary oestrogen and progesterone metabolites to estimate day of ovulation. *Stat. Med.*, **10**, 255-266.

Barbe, F., Legagneur, H., Watrin, V., Klein, M. and Badonnel, Y. (1995) Undetectable luteinizing hormone levels using a monoclonal immunometric assay. *J. Endocrinol. Invest.*, **18**, 806-808.

10

Birken, S., Armstrong, E.G., Kolks, M.A., Cole, L.A., Agosto, G.M., Krichevsky, A., Vaitukaitis, J.L. and Canfield, R.E. (1988) Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine. *Endocrinology*, **123**, 572-583.

15

Birken, S., Chen, Y., Gawinowicz, M.A., Agosto, G.M., Canfield, R.E. and Hartree, A.S. (1993) Structure and significance of human luteinizing hormone-beta core fragment purified from human pituitary extracts. *Endocrinology*, **133**, 985-989.

20

Birken, S., Kovalevskaya, G. and O'Connor, J. (1996a) Metabolism of hCG and hLH to multiple urinary forms. *Molecular Cellular Endocrinology*, **125**, 121-131.

25

Birken, S., Maydelman, Y., Gawinowicz, M.A., Pound, A., Liu, Y. and Hartree, A.S. (1996b) Isolation and

-103-

characterization of human pituitary chorionic gonadotropin. *Endocrinology*, **137**, 1402-1411.

- 5 Blithe, D.L., Akar, A.H., Wehmann, R.E. and Nisula, B.C. (1988) Purification of beta-core fragment from pregnancy urine and demonstration that its carbohydrate moieties differ from those of native human chorionic gonadotropin-beta. *Endocrinology*, **122**, 173-180.
- 10 Cano, A. and Aliaga, R. (1995) Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood. *Hum. Reprod.*, **10**, 63-67.
- 15 Costagliola, S., Niccoli, P. and Carayon, P. (1994) Glycoprotein hormone isomorphism and assay discrepancy: the paradigm of luteinizing hormone (LH). [Review]. *J. Endocrinol. Invest.*, **17**, 291-299.
- 20 de Medeiros, S.F., Amato, F. and Norman, R.J. (1991) Stability of immunoreactive beta-core fragment of hCG. *Obstet. Gynecol.*, **77**, 53-59.
- 25 Edwards, R.G., Steptoe, P.C. and Purdy, J.M. (1980) Establishing full-term human pregnancies using cleaving embryos grown in vitro. *Br. J. Obstet. Gynaecol.*, **87**, 737-756.

-104-

Flete, D., Srivastava V., Hindsgaul O. and Baenziger, J.U. (1991) A hepatic reticuloendothelial cell receptor specific for SO₄-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha that mediates rapid clearance of lutropin [see comments].
5 *Cell*, 67, 1103-1110.

Iles, R.K., Lee, C.L., Howes, I., Davies, S., Edwards, R. and Chard, T. (1992) Immunoreactive beta-core-like material in normal postmenopausal urine: human chorionic gonadotrophin or LH origin? Evidence for the existence of
10 LH core. *J. Endocrinol.*, 133, 459-466.

Kato, Y. and Braunstein, G.D. (1988) Beta-core fragment is a major form of immunoreactive urinary chorionic gonadotropin in human pregnancy. *J. Clin. Endocrinol. Metab.*, 66, 1197-1201.
15

Kawasaki, T. and Ashwell, G. (1976) Chemical and physical properties of an hepatic membrane protein that specifically binds asialoglycoproteins. *J. Biol. Chem.*,
20 251, 1296-1302.

Kesner, J.S., Knecht, E.A., Krieg, E.F., Wilcox, A.J. and O'Connor, J.F. (1997) Detecting previously undetectable preovulatory luteinizing hormone surges in urine. *Hum. Reprod.*, In Press.
25

Kesner, J.S., Knecht, E.A. and Krieg, E.F., Jr. (1995)

-105-

- Stability of urinary female reproductive hormones stored under various conditions. *Reprod. Toxicol.*, 9, 239-244.
- 5 Kesner, J.S., Wright, D.M., Schrader, S.M., Chin, N.W. and Krieg, E.F., Jr. (1992) Methods of monitoring menstrual function in field studies: efficacy of methods. *Reprod. Toxicol.*, 6, 385-400.
- 10 Knobil, E. (1988) The hypothalamic gonadotrophic hormone releasing hormone (GnRH) pulse generator in the rhesus monkey and its neuroendocrine control. [Review] [19 refs]. *Hum. Reprod.*, 3, 29-31.
- 15 Kovalevskaya, G., Birken, S., O'Connor, J., Schlatterer, J., Maydelman, Y. and Canfield, R. (1995) HLH beta core fragment in the urine of ovulating women: a sensitive and specific immunometric assay for its detection. *Endocrine*, 3, 881-887.
- 20 Krichevsky, A., Birken, S., O'Connor, J., Bikel, K., Schlatterer, J., Yi, C., Agosto, G. and Canfield, R. (1991) Development and characterization of a new, highly specific antibody to the human chorionic gonadotropin-beta fragment. *Endocrinology*, 128, 1255-1264.
- 25 Krichevsky, A., Birken, S., O'Connor, J., Bikel, K., Schlatterer, J. and Canfield, R. (1994) The development of a panel of monoclonal antibodies to human luteinizing

-106-

hormone and its application to immunological mapping and two-site assays. *Endocrine*, 2, 511-520.

5 Livesey, J.H., Hodgkinson, S.C., Roud, H.R. and Donald, R.A. (1980) Effect of time, temperature and freezing on the stability of immunoreactive LH, FSH, TSH, growth hormone, prolactin and insulin in plasma. *Clin. Biochem.*, 13, 151-155.

10 Livesey, J.H., Roud, H.K., Metcalf, M.G. and Donald, R.A. (1983) Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine. *J. Endocrinol.*, 98, 381-384.

15 Martin-Du-Pan, R.C., Horak, M. and Bischof, P. (1994) Clinical significance of invisible or partially visible luteinizing hormone. *Hum. Reprod*, 9, 1987-1990.

20 Mitchell, R., Hollis, S., Crowley, V., McLoughlin, J., Peers, N. and Robertson, W.R. (1995) Immunometric assays of luteinizing hormone (LH): differences in recognition of plasma LH by anti-intact and beta-subunit-specific antibodies in various physiological and pathophysiological situations. *Clin. Chem.*, 41, Pt 1):1139-45.

25

Munro, C.J., Stabenfeldt, G.H., Cragun, J.R., Addiego, L.A., Overstreet, J.W. and Lasley, B.L. (1991) Relationship of serum estradiol and progesterone

-107-

concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. *Clin. Chem.*, **37**, 838-844.

5 Neven, P., Iles, R.K., Howes, I., Sharma, K., Shepherd, J.H., Edwards, R., Collins, W.P. and Chard, T. (1993) Substantial urinary concentrations of material resembling beta-core fragment of chorionic gonadotropin beta-subunit in mid-menstrual cycle. *Clin. Chem.*, **39**, 1857-1860.

10

Nisula, B.C., Blithe, D.L., Akar, A., Lefort, G. and Wehmann, R.E. (1989) Metabolic fate of human choriogonadotropin. [Review], *J. Steroid Biochem.*, **33**, 733-737.

15

O'Connor, J.F., Birken, S., Lustbader, J.W., Krichevsky, A., Chen, Y. and Canfield, R.E. (1994) Recent advances in the chemistry and immunochemistry of human chorionic gonadotropin: impact on clinical measurements. [Review].
20 *Endocr. Rev.*, **15**, 650-683.

25

Pettersson, K., Ding, Y.Q. and Huhtaniemi, I. (1991) Monoclonal antibody-based discrepancies between two-site immunometric tests for lutropin. *Clin. Chem.*, **37**, Pt 1):1745-8.

Pettersson, K., Ding, Y.Q. and Huhtaniemi, I. (1992) An immunologically anomalous luteinizing hormone variant in a healthy woman. *J. Clin. Endocrinol. Metab.*, **74**,

-108-

164-171.

Pettersson, K.S. and Soderholm, J.R. (1991) Individual differences in lutropin immunoreactivity revealed by monoclonal antibodies [see comments]. *Clin. Chem.*, **37**, 333-340.

Saketos, M., Sharma, N., Adel, T., Raghuwanshi, M. and Santoro, N. (1994) Evaluation of time-resolved immunofluorometric assay and specimen storage conditions for measuring gonadotropins. *Clin Chem.*, **40**, 749-753.

Schroeder, H.R. and Halter, C.M. (1983) Specificity of human beta-choriogonadotropin assays for the hormone and for an immunoreactive fragment present in urine during normal pregnancy. *Clinical. Chemistry.* **29**, 667-671.

Shoham, Z., Schacter, M., Loumaye, E., Weissman, A., MacNamee, M. and Insler, V. (1995) The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering. [Review]. *Fertil. Steril.*, **64**, 237-251.

Steer, C.J. and Ashwell, G. (1986) Hepatic membrane receptors for glycoproteins. [Review]. *Prog. Liver Dis.*, **8**, 99-123.

-109-

- Tausky, H.H. (1954) A microcolorimetric determination of creatinine in urine by the Jaffe reaction. *J. Biol. Chem.*, **208**, 853-861.
- 5 Van Dieten, J.A.M.J. and De Koning, J. (1995) From basal luteinizing hormone (LH) concentrations to the pre-ovulatory LH surge: Titration of the physiological effect of gonadotrophin surge-inhibiting attenuating factor. *Hum. Reprod.*, **10**, 3110-3116.
- 10 Weiss, P. and Ashwell, G. (1989) The asialoglycoprotein receptor: properties and modulation by ligand. [Review], *Prog. Clin. Biol. Res.*, **300**, 169-184.
- 15 Westhoff, C., Levin, B., Ladd, G. and O'Connor, J. (1992) Sources of variability in normal CA 125 levels. *Cancer Epidemiology, Biomarkers. & Prevention.*, **1**, 357-359.
- 20 Wilcox, A.J., Baird, D.D., Weinberg, C.R., Armstrong, E.G., Musey, P.I., Wehmann, R.E. and Canfield, R.E. (1987) The use of biochemical assays in epidemiologic studies of reproduction. *Environ. Health Perspect.*, **75**, 29-35.

-110-

What is claimed is:

1. A method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising the steps of:
 - a. contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf;
 - b. measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf in the sample; and
 - c. comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject.
2. The method of claim 1, wherein step (a) comprises contacting the sample with an antibody which specifically binds a region of hLH β cf comprising a protein or both protein and carbohydrate moiety.

-111-

3. The method of claim 1, wherein the antibody is monoclonal antibody B505 produced by hybridoma B505 (ATCC No. 12000).
- 5 4. The method of claim 1, wherein in step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.
- 10 5. The method of claim 1, wherein the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.
- 15 6. The method of claim 4, wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
- 20 7. The method of claim 6, wherein the detectable marker is the radioactive isotope I¹²⁵.
- 25 8. A method for predicting the likely timing of the onset of menopause for a perimenopausal female subject comprising the steps of:
- 30 a. contacting a urine sample from the subject with a capturing antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf under conditions permitting binding of the antibody with any

-112-

hLH β cf present in the sample wherein the capturing antibody is bound to a matrix

- b. separating hLH β cf bound to the matrix bound capturing antibody from hLH β cf not so bound;
- 5 c. contacting the hLH β cf bound matrix to the capturing antibody with a second antibody which specifically binds to hLH β cf that is bound to the capturing antibody without cross reacting with hLH, hLH β or hCG β cf under conditions
10 permitting binding of the second antibody to hLH β cf bound to the capturing antibody;
- d. measuring the amount of the second antibody bound to the hLH β cf that is bound to the matrix bound capturing antibody so as to thereby
15 determine the amount of hLH β cf in the sample; and
- e. comparing the amount of hLH β cf in the subject's sample determined in step (d) with either (i) the amount determined for a sample from a known
20 postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH β cf in the sample similar to amount of hLH β cf in the known postmenopausal sample
25 indicates temporal proximity to the onset of menopause, and the amount of hLH β cf in the sample similar to the amount of hLH β cf in the known premenopausal sample indicates temporal
30 distance from the onset of menopause for the subject.

9. The method of claim 8, wherein step (a) the capturing antibody specifically binds a region of hLH β cf

-113-

comprising a protein portion or both a protein and a carbohydrate moiety.

- 5 10. The method of claim 9, wherein the capturing antibody is monoclonal antibody B505 produced by hybridoma B505 (ATCC No. 12000).
11. The method of claim 8, wherein separating hLH β cf bound to the matrix bound capturing antibody from unbound hLH β cf:
- 10 a. removing of the sample from contact with the matrix; and
- b. washing the matrix with an appropriate buffer to remove unbound hLH β cf.
- 15 12. The method of claim 8, wherein the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.
- 20 13. The method of claim 8, wherein the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.
- 25 14. The method of claim 8, wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
- 30 15. The method of claim 14, wherein the radioactive isotope is I¹²⁵.

-114-

16. A method for determining the likely timing of the onset of menopause for a perimenopausal female subject comprising:
- a. obtaining a series of samples from the female subject over a period of time; and
 - b. determining the amount of hLH β cf in each of the samples, the presence of elevated levels of basal hLH β cf in each of the samples indicating that the onset of menopause in the subject is likely to occur in the near future.
17. The method of claim 16, wherein step (b) comprises:
- a. contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β , or hCG β cf, under conditions permitting formation of complex between the antibody and hLH β cf; and
 - b. measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf in the samples; and
 - c. comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, the stable presence of elevated levels of basal hLH β cf indicating temporal distance from the onset of menopause in the subject.
18. The method of claim 17, wherein step (a) the capturing antibody specifically binds a region of hLH β cf comprising a protein portion or both a protein and a carbohydrate moiety.

-115-

19. The method of claim 17, wherein in step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.
20. The method of claim 17, wherein the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, an aggregate sample of the first morning void urine samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.
21. The method of claim 17, wherein the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.
22. The method of claim 17, wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
23. The method of claim 21, wherein the detectable marker is the radioactive isotope is I^{125} .
24. A method for assessing ovarian function in a subject comprising the steps of:
- a. contacting a sample from a subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting

-116-

formation of a complex between the antibody and hLH β cf;

5 b. measuring the amount of complex formed, so as to thereby determine the amount of molecule in the sample; and

10 c. comparing the amount of hLH β cf in the subject's sample determined in step (b) with either (i) the amount determined for a sample from a subject with normal ovarian function or (ii)
15 the amount determined for a sample from a subject with abnormal ovarian function, wherein an amount of hLH β cf in the sample similar to amount of hLH β cf in the sample from subjects having normal ovarian function indicates normal
 ovarian function, and amounts of hLH β cf in the sample similar to amounts of hLH β cf having abnormal ovarian function indicates abnormal ovarian function for the subject.

20 25. The method of claim 24, wherein step (a) the capturing antibody specifically binds a region of hLH β cf comprising a protein portion or both a protein and a carbohydrate moiety.

25 26. The method of claim 24, wherein in step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.

30 27. The method of claim 24, wherein the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days or an aggregate sample of the first morning void urine

-117-

samples for five or more consecutive days, or a collection of all urinations consecutively with time noted for 24-48 hours.

- 5 28. The method according to claim 24, wherein the abnormal ovarian function is hyperactivity.
29. The method according to claim 24, wherein the abnormal ovarian function is hypoactivity.
- 10 30. The method of claim 24, wherein the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively
- 15 31. The method of claim 30, wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
32. The method of claim 31, wherein the detectable marker is the radioactive isotope is I^{125} .
- 20 33. A method for determining the efficacy of hormone replacement therapy in a perimenopausal female subject comprising the steps of:
 - 25 a. contacting a sample from the subject with an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf;
 - b. measuring the amount of complex formed, so as to thereby determine the amount of hLH β cf; and
 - 30 c. comparing the amount of hLH β cf measured in step (b) with either (i) the amount determined for a

-118-

sample from a subject taken prior to the commencement of therapy or (ii) the amount determined for a sample after a prior course of therapy (iii) the amount determined for a sample from a known premenopausal female subject or (iv) the amount determined for a sample from a known postmenopausal female, wherein differences in the amounts of hLH β cf in the sample indicate efficacy of the hormone replacement therapy for the subject; amounts of hLH β cf in the sample similar to amounts of hLH β cf samples from known premenopausal subjects indicates efficacy of the hormone replacement therapy for the subject; amounts of hLH β cf molecule in the sample similar to amounts of hLH β cf in the sample from known postmenopausal subjects indicates lack of efficacy of the hormone replacement therapy for the subject.

34. The method of claim 33, wherein step (a) the capturing antibody specifically binds a region of hLH β cf comprising a protein portion or both a protein and a carbohydrate moiety.

35. The method of claim 33, wherein in step (a) the antibody is bound to a solid support and in step (b) the amount of the antibody bound to the solid support in the complex with hLH β cf is measured by contacting the complex with a second antibody which binds to the complex and which is labeled with a detectable marker.

36. The method of claim 33, wherein the sample is a urine sample, a first morning void urine sample, an aggregate sample of the first morning void urine samples for at least two consecutive days, or an aggregate sample of the first morning void urine samples for five or more consecutive days, or a

-119-

collection of all urinations consecutively with time noted for 24-48 hours.

37. The method of claim 33, wherein the replacement hormone therapy comprises therapy with estrogen.
- 5 38. The method of claim 33, wherein the second antibody labeled with a detectable marker is monoclonal antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.
- 10 39. The method of claim 38, wherein the detectable marker is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
40. The method of claim 39, wherein the detectable marker is the radioactive isotope is I^{125} .
- 15 41. A diagnostic kit for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH β cf in a sample from the subject comprising:
- 20 a. a solid matrix to which an antibody which specifically binds to hLH β cf without substantially cross-reacting with hLH, hLH β or hCG β cf, under conditions permitting formation of a complex between the antibody and hLH β cf is bound; and
- 25 b. a second antibody labeled with a detectable marker; and
- c. reagents permitting the formation of a complex between the antibody and hLH β cf.
- 30 42. The diagnostic kit of claim 41, further comprising control sample(s) selected from the group consisting

-120-

of premenopausal sample(s), perimenopausal sample(s), postmenopausal sample(s) and male sample(s).

43. The diagnostic kit of claim 41, wherein the second antibody is labeled with a detectable marker is antibody B503 or B504 produced by hybridomas B503 (ATCC No. 11999) and B504 (ATCC No. 12002) respectively.

44. The diagnostic kit of claim 41, wherein the detectable marker is a radioactive isotope, enzyme, magnetic bead, dye or biotin.

45. The diagnostic kit of claim 41, wherein the detectable marker is the radioactive isotope is I^{125} .


1/39

FIG. 1

~~Ser-Arg-Glu-Pro-Leu~~ Arg-Pro-Trp-Cys-His-Pro-Ile-Asn-Ala-Ile-Leu-Ala-Val-Glu-Lys-Glu-Gly
 20
 23
 Cys-Pro-Val-Cys-Ile-Thr-Val-Asn-Thr-Thr-Ile-Cys-Ala-Gly-Tyr-Cys-Pro-Phe-Met-Met-Arg-Val
 45
~~Leu-Glu-His-Val~~ Leu-Pro-Pro-Leu-Pro-Gln Val-Val-Cys-Thr-Tyr-Arg-Asp-Val-Arg-Phe-Glu-Ser-
 67
 Ile-Arg-Leu-Pro-Gly-Cys-Pro-Arg-Gly-Val-Asp-Pro-Val-Val-Ser-Phe-Pro-Val-Ala-Leu-Ser-Cys-
 89
 Arg-Cys-Gly-Pro-Cys Arg-Arg-Ser-Thr-Ser-Asp-Cys-Gly-Gly-Pro-Lys-Asp-His-Pro-Leu-Thr
 111
~~Cys-Asp-His-Pro-Gln-Pro-Gln~~ Pro-Gln-Leu-Ser-Gly-Leu-Leu-Phe

2/39

FIG. 2




- Pituitary B505 activity (HLHβcf)
- Periiovulatory urine B505 activity
- Postmenopausal urine B505 activity

3/39

FIG. 3A


MJB FMV Normal Premenopausal



4/39

FIG. 3B


pat #144 FMV premenopausal



5/39

FIG. 3C


Pt 100 FMV Premenopausal



6/39

FIG. 3D


Patient 2 FMV Premenopausal



7/39

FIG. 3E


Pt 3793 FMV Premenopausal



8/39

FIG. 3F


Pt 169 FMV Premenopausal



9/39

FIG. 3G


Pt 137 FMV Premenopausal



10/39

FIG. 3H


Perimenopausal 2222 (D.M.)



11/39

FIG. 31


Pat 0697 Perimenopausal (DM)



12/39

FIG. 3J


AE FMV Postmenopausal Urines



13/39


FIG. 3K

Barnell Postmenopausal FMV Urines



14/39

FIG. 4



15/39

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D





FIG. 5E

16/39

FIG. 6



17/39

Patient #75-3

FIG. 7C





FIG. 7D

Patient #67-5

FIG. 7A








FIG. 7B

18/39


FIG. 8





20/39

FIG. 10



21/39

FIG. 11A





FIG. 11B



○ HLH-1 △ HLH β
□ HLH-2 ● HLH β cf

22/39

FIG. 12A




FIG. 12B





FIG. 12C



23/39

FIG. 13A




FIG. 13B






FIG. 13C



24/39

FIG. 14A


LK FMV Urines Before ERT



Area = 3050

25/39

FIG. 14B
LK FMV Urines After ERT




Area = 1650

26/39

FIG. 14C


VP FMV Urines Before ERT



Area = 1350

27/39

FIG. 14D
VP FMV Urines After ERT




Area = 280

28/39

FIG. 14E

NP FMV Urines hLHbcf before ERT




Area = 3200

29/39

FIG. 14F

NP FMV URines After ERT



Area = 3260

30/39

FIG. 15A






FIG. 15B



31/39

FIG. 16A





FIG. 16B

Day of Urine Collection

32/39

FIG. 17A





FIG. 17B

Day of Urine Collection

33/39

FIG. 18A







FIG. 18C

Day of Urine Collection


34/39



35/39

FIG. 20A


3010 postmenopausal woman spot urine samples



36/39

FIG. 20B


3013 spot urine samples of postmenopausal woman



37/39

FIG. 20C


3018 Postmenopausal Spot Urines Samples



38/39

FIG. 20D


3034 postmenopausal woman spot urine samples



39/39

FIG. 20E

3039 spot urines of postmenopausal woman



SEQUENCE LISTING

<110> The Trustees of Columbia University in The City of

<120> Determination of the Amount of hLHB Core Fragment in a
Sample from a Subject and Uses Thereof

<130> 54204-A-PCT

<140>

<141>

<150> 09/018,122

<151> 1998-02-03

<160> 2

<170> PatentIn Ver. 2.0 - beta

<210> 1

<211> 122

<212> PRT

<213> Homo sapiens

<400> 1

Ser	Arg	Glu	Pro	Leu	Arg	Pro	Trp	Cys	His	Pro	Ile	Asn	Ala	Ile	Leu
1				5					10					15	

Ala	Val	Glu	Lys	Glu	Gly	Cys	Pro	Val	Cys	Ile	Thr	Val	Asn	Thr	Thr
		20					25						30		

Ile	Cys	Ala	Gly	Tyr	Cys	Pro	Thr	Met	Met	Arg	Val	Leu	Gln	Ala	Val
	35						40					45			

Leu	Pro	Pro	Leu	Pro	Gln	Val	Val	Cys	Thr	Tyr	Arg	Asp	Val	Arg	Phe
	50					55					60				

Glu	Ser	Ile	Arg	Leu	Pro	Gly	Cys	Pro	Arg	Gly	Val	Asp	Pro	Val	Val
65					70					75					80

Ser	Phe	Pro	Val	Ala	Leu	Ser	Cys	Arg	Cys	Gly	Pro	Cys	Arg	Arg	Ser
			85						90					95	

Thr	Ser	Asp	Cys	Gly	Gly	Pro	Lys	Asp	His	Pro	Leu	Thr	Cys	Asp	His
			100					105					110		

Pro	Gln	Pro	Gln	Leu	Ser	Gly	Leu	Leu	Phe
	115						120		

<210> 2

<211> 80

<212> PRT

<213> Homo sapiens

<400> 2

Arg Pro Trp Cys His Pro Ile Asn Ala Ile Leu Ala Val Glu Lys Glu
1 5 10 15

Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr
20 25 30

Cys Pro Thr Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg Asp
35 40 45

Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp
50 55 60

Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Gly Pro Cys
65 70 75 80

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02279

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6): G01N 33/53, 33/537, 33/541, 33/543, 33/493; C07K 16/26

US CL: 436/501, 518, 538, 540, 542; 530/387.1, 388.24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S.: 436/501, 518, 538, 540, 542; 530/387.1, 388.24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN, MEDLINE, EMBASE, BIOSIS, WPIDS

search terms: lutenizing hormone or lh, human, core fragment, postmenopausal or postmenopause or menopause or meopausal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIRKEN et al. Metabolism of hCG and hLH to multiple urinary forms. Molecular and Cellular Endocrinology. 1996, Vol. 125, pages 121-131, especially page 126, column 2.	41-45
A	ILES et al. Immunoreactive b-core-like material in normal postmenopausal urine: human chorionic gonadotrophin or LH origin? Evidence for the existence of LH core. Journal of Endocrinology. 1992, Vol. 133, pages 459-466, especially page 463, column 2.	1-45

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 16 MARCH 1999	Date of mailing of the international search report 25 MAR 1999
--	---

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
Christine Saoud
CHRISTINE SAOUD
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02279

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HEE et al. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol, and progesterone. Maturitas. 1993, Vol. 18, pages 9-20, especially page 19.	1-45
A	SANTORO et al. Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab. 1996, Vol. 81, No. 4, pages 1495-1501, especially page 1499.	1-45

This Page Blank (uspto)